Page last updated: 2024-08-22

angiotensin ii and Diabetes Mellitus, Type 2

angiotensin ii has been researched along with Diabetes Mellitus, Type 2 in 218 studies

Research

Studies (218)

Timeframe	Studies, this research(%)	All Research%
pre-1990	3 (1.38)	18.7374
1990's	24 (11.01)	18.2507
2000's	108 (49.54)	29.6817
2010's	70 (32.11)	24.3611
2020's	13 (5.96)	2.80

Authors

Authors	Studies
Asmar, A; Christ-Crain, M; Jensen, BL; Sailer, CO; Vogt, DR; Vukajlovic, T; Winzeler, B	1
Azizian, H; Bashiri, H; Ebrahimi, MN; Khaksari, M; Raji-Amirhasani, A	1
Chen, F; Hou, Z; Liu, G; Lu, Y; Lv, X; Xing, C; Zhang, C; Zhang, D	1
Ahmad, S; Ferrario, CM; Meredith, WJ; Saha, A; VonCannon, JL	1
Nguyen, J; Vandemark, C; Zhao, ZQ	1
Anand, P; Bhati, P; Deepak, KK; Hussain, ME; Masood, S	1
Geng, M; Jiang, X; Liu, W; Tan, Z; Xin, Y	1
Azemi, AK; Mokhtar, SS; Rasool, AHG; Wee, CL; Yaacob, NS; Yahaya, S	1
Addison, ML; Ranasinghe, P; Webb, DJ	1
Guo, L; Tian, L; Zhang, J	1
Abouelkheir, M; El-Metwally, TH	1
Baqar, S; Chen, AX; Ekinci, EI; Jerums, G; Libianto, R; MacIsaac, RJ; Moran, JL; O'Callaghan, C	1
Córdova, S; Farías, L; Gabrielli, L; García, L; Godoy, I; Jalil, JE; Moya, J; Nab, PM; Ocaranza, MP; Valderas, P	1
Aasen, T; Abdul Moin, NI; Abdul Wafi, S; Aboukameel, A; Abu-Bakar, N; Acharya, A; Ackermans, L; Adaramoye, O; Adarsh, KV; Adeosun, WA; Ahmad, NH; Ahmadi, F; Akanni, O; Akbar, M; Akbulak, RO; Akev, N; Akkaya, Ö; Al-Rashed, S; AlAbbad, S; Alabi, O; Alappat, BJ; Alcalá, S; Alcoutlabi, M; Aleppo, G; Alexander Ross, JB; Alexander, JH; Alexander, R; Alias, A; Alimba, C; Alken, FA; Allan, R; Alpers, M; Alsbou, EM; Amarasiri, SS; An, T; Anastasiadis, F; Anastassiadou, M; Anderson, KC; Andronikos, P; Anheyer, D; Annapurna, K; Anorlu, RI; Anten, MM; Anthopoulos, TD; Araujo-Castillo, RV; Aravamudhan, S; Arawwawala, LDAM; Arulsamy, N; Arunamata, A; Asghar, A; Asiri, AM; Aslanidou, T; Astrakhantseva, IV; Astutik, E; Attanayake, AP; Atwater, BD; Audureau, E; Augusto, S; Bakare, A; Banach, M; Bandelier, P; Banerjee, S; Barral, M; Bascuñán, J; Bates, FS; Bauer, NJC; Bayrak, BB; Beck, RW; Beckervordersantforth, J; Beeri, R; Begum, R; Beldi-Ferchiou, A; Bellingham, G; Ben-Tal, N; Bendib, I; Bergenstal, RM; Berger, MF; Bernasconi, G; Berry, S; Beuvon, F; Bi, WJ; Bi, Z; Bianconi, V; Bibi, I; Blank, BR; Bliemeister, E; Bobkowski, W; Bode, AM; Booth, CM; Bose, U; Boyd, K; Brancato, A; Brenmoehl, J; Brogi, E; Bronzo, P; Brooks, T; Brown, D; Brown, DN; Bruce, D; Buan, MEM; Bueno-Hernández, F; Bugielski, B; Bulavaitė, A; Buscagan, TM; Buxton, R; Caffaro, MM; Cai, Q; Cai, X; Cai, Y; Calhoun, P; Callander, N; Cambier, S; Camparo, P; Canales-Vargas, EJ; Canham, K; Cantu, J; Cao, J; Cao, JW; Cao, P; Cao, T; Cao, X; Caravella, BA; Carcadea, E; Carè, J; Carmichael, P; Carrasco Cabrera, L; Carteaux, G; Carvalho, PDS; Casarez, E; Cazorla, M; Celestrin, CP; Chakraborty, NK; Chan, B; Chandarlapaty, S; Chandgude, AL; Chang, CC; Chang, JH; Chang, X; Chang, Y; Chankhanittha, T; Chantanis, S; Chapovetsky, A; Chavan, S; Chen, B; Chen, D; Chen, F; Chen, G; Chen, H; Chen, J; Chen, K; Chen, KJ; Chen, KP; Chen, L; Chen, MA; Chen, Q; Chen, S; Chen, W; Chen, WF; Chen, X; Chen, Y; Cheng, D; Cheng, J; Cheng, Q; Cheon, GJ; Chiu, SC; Cho, CH; Cho, J; Choi, H; Choi, JS; Choi, YH; Christie, P; Chu, CH; Chu, Y; Chung, DH; Chung, F; Cline, JP; Cohen, A; Cohen, AD; Cohen, NJ; Comen, E; Compter, I; Cong, J; Cong, Z; Cooper, A; Cornud, F; Costa, C; Costa, S; Covey, A; Cowan, AM; Cramer, H; Cruz-Rivera, C; Cui, J; Cui, M; Cui, Y; Cui, YH; Culquichicón, C; Cushman, T; D'Auria, SJ; da Silva, J; Dalgediene, I; Danenberg, HD; Das, S; Dasgupta, K; Daubit, IM; de Oliveira, PD; de Prost, N; De Ruysscher, D; Dearman, K; Decato, D; Delfau-Larue, MH; Deng, L; Dhakate, SR; Dharuman, V; Di Costanzo, N; Dickler, MN; Dinehart, EE; Ding, D; Dinh, TK; Divya, KP; Djifack Tadongfack, T; Do, T; Domínguez-Roldan, R; Domínguez-Zambrano, E; Dömling, A; Donato, MD; Dong, JH; Dong, W; Dong, X; Dong, XR; Dong, Y; Dong, Z; Downs, M; Drutskaya, MS; Du, B; Du, F; Du, H; Du, L; Du, X; Duan, Z; Duangthip, D; Dunstand-Guzmán, E; Duong, F; Eckert, DJ; Edelhäuser, BAH; Eekers, DBP; Efendi, F; Efraimidis, P; Ehrenberg, H; Ehsanbakhsh, Z; Eickholt, C; Eksterowicz, J; El Mobadder, M; El-Araby, IE; El-Magd, MA; El-Tarabany, MS; Elgorban, AM; Engelmann, D; English, KL; Esfandiari, H; Eslami, B; Espinosa-Cuevas, A; Eswara, S; Faber, E; Fan, XH; Fan, Y; Fang, J; Fang, Z; Fantin, VR; Fei, P; Feng, G; Feng, H; Feng, J; Feng, X; Feng, XJ; Fennell, TR; Fernández-Moreira, V; Ferraz, ABF; Ferreras, KN; Flores, K; Flores-Pérez, I; Flox, C; Fluharty, FL; Fokouong Tchoffo, E; Folefack, GO; Foroutan, T; Fort, D; Fourati, S; Fousas, S; Frapard, T; Freguia, S; Friedman, DJ; Friedman, LS; Fu, D; Fu, Q; Fu, Y; Fujinami, S; Furihata, K; Gal, RL; Gan, H; Gao, C; Gao, F; Gao, R; Gao, SS; Gao, W; Gao, XC; Gao, Y; Gao, Z; Garozi, L; Ge, J; Georgiopoulos, A; Gerakiou, K; Ghazimirsaeed, SM; Ghazimirsaeed, ST; Gimeno, MC; Gjestad, R; Glurich, I; Goetchius, E; Goland, S; Goldstein, S; Gonçalves, CM; Gonçalves, H; Gong, Q; Gonzalez, D; Goplen, FK; Gorshkova, EN; Gotsman, I; Govindasamy, V; Granger, CB; Greco, L; Grigoriadou-Skouta, E; Grigoropoulos, P; Grivicich, I; Gromov, NV; Gruber, S; Grytczuk, M; Grzech-Leśniak, K; Gu, L; Gu, S; Gu, Z; Guadagnini, D; Guan, H; Guilliams, M; Guo, J; Guo, L; Gupta, A; Gupta, SK; Gurzu, S; Gutleb, AC; Haban, A; Hablitz, JJ; Hadisuyatmana, S; Hahn, S; Haiges, R; Hallal-Calleros, C; Hamed, M; Hammad, N; Hammer, N; Han, C; Hao, Y; Harnett, J; Has, EMM; Hassanpour, K; Hatzopoulos, D; Hawaldar, R; He, X; He, Y; He, YY; He, Z; Heberman, D; Heckl, D; Hegde, H; Henson, MA; Hernández-Velázquez, VM; Herrera, E; Hijazi, Z; Hirayama, K; Hirth, JM; Hoeben, A; Hohnloser, SH; Hong, M; Hood, K; Hoplock, LB; Hopman, WM; Horlbogen, LM; Hossein Rashidi, B; Hou, G; Hou, H; Hou, J; Hou, Y; Hu, J; Hu, W; Hu, X; Hua, W; Huang, G; Huang, H; Huang, J; Huang, T; Huang, W; Huang, Y; Huang, YD; Huang, Z; Hudis, CA; Hue, S; Huo, J; Hussain, M; Hvas, AM; Ichii, T; Ide Zeuna, J; Ilyas, S; Inoue, T; Iranzo, A; Irfan, M; Iwasa, Y; Iwashita, Y; Izgorodina, EI; J R, A; Jaber, WA; Jaborek, JR; Jacobus, SJ; Jadeja, SD; Jafarabadi, M; Jalan, D; Jamil, MI; Jarrah, S; Jarvis, D; Jayatilaka, KAPW; Jemal-Turki, A; Jeon, YK; Jeong, N; Jeong, SH; Jeong, SY; Jermy, M; Jhaveri, K; Ji, H; Ji, K; Ji, RY; Jiang, F; Jiang, J; Jiang, X; Jiang, Y; Jiao, Q; Jilani, K; Jiménez-Guerrero, P; Jin, L; Jo, YH; Johnson, JG; Johnson, ML; Jones, WS; Jose, S; Jularic, M; Jung, I; Jung, YJ; Jungen, C; Junttila, MR; Kache, S; Kahanovitch, U; Kalantzi, KI; Kallio, T; Kamnoedboon, P; Kang, CH; Kang, H; Kang, J; Kang, KW; Kapoor, P; Karmakar, D; Kartalis, A; Kauranen, P; Kazocina, A; Keikha, F; Keltai, M; Kershaw, SV; Kettani, M; Khalvati, S; Khandhar, S; Khosla, N; Kiely, CJ; Kim, CC; Kim, H; Kim, MJ; Kim, Y; Kim, YH; Kim, YT; Kimoto, E; Kiyu, A; Klatt, N; Kobayashi, M; Koh, J; Köhler, R; Kondadasula, SV; Kong, H; Kong, W; Kong, X; Kotidis, A; Kotwal, A; Kouvari, M; Kozhinov, AN; Kruger, D; Kuang, S; Kuang, Y; Kubota, M; Kuklik, P; Kumar, P; Kumar, SK; Kuo, YF; Kurup, SP; Kusuhara, H; Kuswanto, H; Lacouture, ME; Lambin, P; Lang, CC; Langroudi, FH; Lanman, RB; Larsen, OH; Laskin, J; Le, VH; Leach, M; Lee, BG; Lee, DF; Lee, DS; Lee, HJ; Lee, SB; Lee, YA; Lei, Y; Lekashvili, O; Lelj, F; Lemin, AS; Lemoine, J; Leuschner, R; Li, B; Li, BT; Li, C; Li, D; Li, F; Li, G; Li, H; Li, HW; Li, J; Li, M; Li, P; Li, Q; Li, S; Li, W; Li, X; Li, XY; Li, Y; Li, Z; Lian, Y; Liang, C; Liao, J; Liao, W; Liao, Y; Lin, D; Lin, W; Lin, YL; Lindbäck, J; Lindsay, AP; Ling, J; Linser, PJ; Liu, C; Liu, H; Liu, JJ; Liu, L; Liu, Q; Liu, SF; Liu, X; Liu, Y; Liu, Z; Liu, ZM; Lo Sterzo, C; Lo, ECM; Lobchuk, MM; Lodge, TP; Logotheti, S; Lonial, S; Lopes, G; Lopes, RD; Lopez, J; Lopez, SA; López-Santos, AL; López-Sendón, JL; Loring, Z; Louis, C; Lovita, AND; Lu, DZ; Lu, H; Lu, J; Lu, K; Lu, TT; Lu, Y; Luengo, A; Lum, LG; Luna, JM; Luo, L; Luo, R; Luo, T; Luo, X; Luo, Z; Lv, B; Lymperopoulos, N; Lyras, A; Lyu, Y; M Kannan, A; Ma, H; Ma, M; Ma, Q; Ma, S; Ma, WY; Ma, Y; Maalouf, E; Machado, FA; Maeda, K; Magrans, JO; Maharani, A; Maia, G; Mainwaring, RD; Maji, TK; Majumdar, K; Mannarino, MR; Mansuri, MS; Marinescu, SC; Markatos, G; Marquardt, S; Marraiki, N; Martens, C; Martínez, TJ; Marumo, K; Maruyama, H; Marwani, HM; Marzo, I; Masrati, G; Matamba, P; Mathialagan, S; Matys, J; Mayatra, JM; Mboua, PC; McArthur, T; McCrimmon, RJ; McIntosh, S; McSpadden, S; Medina-Campos, ON; Medvedovsky, AT; Mei, Z; Mekontso-Dessap, A; Menezes, AMB; Meng, J; Meng, P; Meng, Y; Menter, A; Mets, MB; Mets-Halgrimson, R; Metzger, T; Metzler-Nolte, N; Meyer, C; Mi, Y; Michailoviene, V; Mikrogeorgiou, A; Militz, H; Miller Iii, TF; Minarowska, A; Mir, S; Miron, I; Miyake, T; Moayer, F; Modi, S; Moeller, SJ; Mohamad, MN; Mohammed, EHM; Mokhonov, VV; Mondal, A; Moore, J; Moravcova, M; Mordi, IR; Mordi, NA; Mortensen, NP; Moscariello, C; Moser, J; Moynahan, ME; Mu, J; Mu, W; Mudduwa, LKB; Mukherjee, S; Mukhtar, A; Mulkey, DK; Murr, N; Mushtaq, Z; Muthuswamy, N; Mutlu, O; Muto, C; Myroforou, I; Na, KJ; Nabi, M; Nagornov, KO; Nagy, RJ; Naik, A; Nakajima, K; Nam, KT; Nam, YW; Namburath, M; Nammour, S; Namour, A; Namour, M; Nanan, S; Natsume, H; Nave, S; Naveed, A; Nazir, H; Ndubaku, C; Nedospasov, SA; Neradilek, MB; Newcomb, C; Nguépy Keubo, FR; Nguyen, M; Ning, J; Ning, Q; Noguchi, S; Nordahl, SHG; Nordfalk, KF; Norton, L; Noupoue, EM; Nouri, SS; Nowak, JK; Núñez, K; Oakes, K; Odegaard, JI; Ogorodnikova, OL; Ogunsuyi, O; Oh, HK; Oh, HR; Oh, KH; Ohgi, K; Okunade, KS; Oliveira, AG; Olorunfemi, G; Olsen, ML; Olson, BA; Omari, KW; Ondruschka, B; Orfali, R; Orkopoulos, A; Orlowski, RZ; Oser, SM; Oser, TK; Özcan, M; Padilla, V; Paeng, JC; Pajuelo-Lozano, N; Pal, SK; Palmieri, S; Palomeque, E; Pan, W; Panagiotakos, DB; Pandey, M; Pang, D; Pang, Q; Pangarah, CA; Panny, A; Paparella, A; Papirio, S; Papouskova, K; Parang, K; Park, HJ; Park, IK; Park, S; Parker, TL; Parkhomenko, A; Parmon, VN; Parsons, B; Parsons, J; Patel, PR; Patil, S; Patsourakos, NG; Patterson, KC; Pavlidis, P; Pedernera, M; Pedersen, R; Pedraza-Chaverri, J; Pellegrini, M; Peña-Chora, G; Pereira, EDM; Pereira, MADS; Peretz, A; Perez-Padilla, R; Perlman, GY; Perona, R; Petras, C; Phuntsho, S; Picada, JN; Pinder, TA; Piper, LFJ; Pirozzi, F; Pirro, M; Pleckaityte, M; Ploutz-Snyder, LL; Ploutz-Snyder, R; Pogorzelski, A; Poles, L; Postma, AA; Prager, A; Prakash, J; Punn, R; Pützer, BM; Qi, J; Qi, MC; Qi, Y; Qian, J; Qian, Y; Qiang, L; Qiu, J; Qu, Y; Rabiu, KA; Rahighi, S; Rahman, MM; Rahmani, B; Rajkumar, SV; Ramanathan, R; Raras, TYM; Rashi, Y; Rasool, G; Rathore, MG; Ratnawati, R; Ratola, N; Raucci, U; Ray, SK; Razavi, P; Razazi, K; Razek, S; Razi, SS; Reback, M; Reddy, K; Rees, DC; Reginatto, FH; Reich, H; Reis-Filho, JS; Ren, X; Ren, Y; Renner, G; Rey, G; Reymen, B; Riaz, M; Ricci, A; Richardson, PG; Richter, C; Riga, M; Ritchie, C; Rivoal, S; Roberts, W; Robson, ME; Rocha, GZ; Rodrigues, AD; Rogach, AL; Rojas, A; Rosenberg, A; Rosenberg, E; Rosenheck, RA; Roslan, K; Rothenberger, C; Rouschop, KMA; Rubagumya, F; Ryan, CM; Ryder, JW; Saad, MJA; Sacan, O; Sacchi, A; Sahebkar, A; Saini, A; Sainz, B; Sajo, EA; Sakizadeh, J; Saleh, AA; Salgado Júnior, IB; Salvi, R; Samoylova, YV; Samuni, A; Sanchez, DM; Sanchez-Perez, I; Santos, M; Sarapulova, A; Sardot, T; Saud, N; Sauerbier, P; Scaltriti, M; Schaeffer, B; Schalk, DL; Scherschel, K; Schijven, MP; Schreuder, HWR; Schuhmacher, M; Schultz-Lebahn, A; Schwarzl, J; Scott, JM; Sebayang, SK; Seeger, ZL; Segabinazi Peserico, C; Selenica, P; Serio, A; Seruga, B; Shah, A; Shah, C; Shah, PD; Shahrokh Tehraninezhad, E; Shan, A; Shao, Z; Sharma, AMR; Sharma, RK; Shen, J; Shen, R; Shi, X; Shi, Y; Shi, ZE; Shih, YC; Shimohata, H; Shimpi, N; Shin, SH; Shon, HK; Shuvy, M; Siddique, AB; Siegbahn, A; Sikandar, M; Silvani, Y; Singh, A; Singh, AK; Singh, D; Singh, JS; Singh, KP; Singh, M; Situ, B; Skipper, MT; Skouloudi, M; Sloane, BF; Smyrnioudis, N; Snyder, MA; Söhnchen, C; Solis Condor, R; Solit, DB; Someya, S; Song, H; Song, J; Song, W; Song, Y; Sorokina, KN; Soshi, S; Soyer, P; Spitschak, A; Sreekrishnan, TR; Srinivasan, M; Staruschenko, A; Steel, A; Stefan-van Staden, RI; Stein, AM; Strayer, H; Struthers, AD; Su, H; Su, Q; Su, X; Sudore, RL; Sugimura, H; Sugiyama, Y; Sujuti, H; Sumner, SJ; Sun, B; Sun, D; Sun, H; Sun, J; Sun, JY; Sun, X; Sun, Y; Sun, Z; Sung, YC; Surenaud, M; Sutimantanapi, D; Suwandaratne, NS; Swaroop, S; Sychrova, H; Syed, A; Szczepanik, M; Szederjesi, J; Szodorai, R; Tacy, TA; Tadelle, RM; Takayasu, M; Tammeveski, K; Tan, H; Tan, M; Tang, HX; Tang, S; Tang, X; Tanokura, M; Tao, F; Tao, H; Tarafdari, A; Tarín-Carrasco, P; Tasson Tatang, C; Teixeira, JP; Thakur, A; Theobald, A; Thevenot, P; Thomaidis, K; Tian, J; Tillib, SV; Toma, C; Tomita, M; Tonchev, I; Tong, F; Toy, W; Trypuć, M; Tselepis, AD; Tsetseris, L; Tsikouri, GE; Tsikouris, EI; Tsoplifack, CB; Tsoumani, ME; Tsujimoto, R; Tsybin, YO; Tu, J; Tu, TM; Turco, M; Turkyilmaz, IB; Uddin, MJ; Ung, J; Unsihuay, D; Utsunomiya, T; Vagenende, B; Vaishnav, J; Valdes, C; Validad, MH; Valle, J; van Ginkel, MPH; van Grevenstein, WMU; Vanderpuye, V; Vasan, N; Vasilenko, EA; Vasques, GJ; Vavoulis, P; Verani, A; Veziroglu, E; Viegas, A; Vitali, MG; Vitsas, G; Voccio, JP; Vogiatzidis, C; Volow, A; Volpin, F; Vourvahis, M; Wagner, LI; Walkowiak, J; Wallace, R; Wallentin, L; Wan, D; Wan, L; Wan, T; Wang, C; Wang, F; Wang, FN; Wang, H; Wang, J; Wang, L; Wang, Q; Wang, S; Wang, T; Wang, W; Wang, X; Wang, XW; Wang, Y; Wang, YS; Wang, Z; Ward, J; Ward, L; Waseem, R; Watson, DF; Weber, P; Wehrmeister, FC; Wei, CH; Wei, H; Wei, L; Wei, Q; Wei, Y; Weinstock, RS; Weiss, M; Welborn, M; Wen, L; Wen, LM; Wen, Q; Wen, Z; Wesseling, P; Westerbergh, J; White, K; Wick, MP; Willems, S; Wiyasa, IWA; Wójciak, R; Wolkenhauer, O; Won, HH; Wong, J; Woo, YC; Wood, LS; Wu, CT; Wu, CY; Wu, D; Wu, G; Wu, J; Wu, K; Wu, M; Wu, Q; Wu, T; Wu, W; Wu, X; Wu, XT; Wu, Y; Xi, D; Xi, J; Xiang, W; Xiang, Y; Xiao, M; Xiao, Z; Xie, H; Xie, Q; Xie, S; Xie, X; Xing, M; Xing, YL; Xu, C; Xu, X; Xu, Y; Xu, Z; Xue, F; Xue, XD; Yaglioglu, HG; Yamada, H; Yamashita, M; Yan, W; Yan, Z; Yanardag, R; Yang, D; Yang, H; Yang, K; Yang, QQ; Yang, R; Yang, S; Yang, T; Yang, X; Yang, Y; Yao, H; Yao, Y; Yari, D; Yassin, MT; Ye, C; Ye, J; Ye, Q; Yildiz, EA; Ying, S; Yoon, H; Yu, D; Yu, K; Yu, N; Yu, PL; Yuan, C; Yuan, D; Yuan, LJ; Yuan, Z; Yuen, N; Zagatto, AM; Zakaria, Y; Zalewski, AM; Zamora, S; Zavorotinskaya, T; Zeid, JL; Zeinoun, T; Zeng, C; Zerby, HN; Zhan, X; Zhang, A; Zhang, D; Zhang, E; Zhang, F; Zhang, H; Zhang, J; Zhang, L; Zhang, M; Zhang, P; Zhang, Q; Zhang, QY; Zhang, RG; Zhang, S; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, CK; Zhao, H; Zhao, J; Zhao, K; Zhao, Q; Zhao, S; Zhao, T; Zhao, XQ; Zhao, Y; Zhao, Z; Zheng, J; Zheng, L; Zheng, Y; Zhou, B; Zhou, G; Zhou, L; Zhou, T; Zhou, X; Zhu, C; Zhu, J; Zhu, Y; Zhu, ZQ; Zhuang, T; Zimmermannova, O; Zin, NNINM; Zisimos, K; Zoghebi, KA; Zonder, JA; Zou, C; Zwirner, J	1
Filipeanu, CM; Lazartigues, E; Ogunlade, BO	1
Chen, H; Hu, R; Liu, C; Shao, J; Xie, P; Yang, D	1
Gong, WQ; Huang, WC; Liang, Y; Liu, B; Yang, CM; Ye, XL; Zheng, YT	1
Jang, HC; Kim, KM; Kong, SH; Lee, DH; Lee, JE; Lim, S; Min, SH; Oh, TJ; Park, KS	1
Chan, SMH; Herbert, TP; Ku, JM; Lau, YS; Miller, AA; Potocnik, S; Woodman, OL; Ye, JM	1
Gaikwad, AB; Goru, SK; Kadakol, A; Malek, V	1
Scherer, PE; Zhu, Q	1
Kasacka, I; Nowińska, P	1
Abraham, NG; Arad, M; Aravot, D; Cohen, K; Gorfil, D; Hochhauser, E; Kornwoski, R; Laniado-Schwartzman, M; Nudelman, V; Waldman, M; Yadin, D	1
Chen, H; Chen, R; Ruan, Y; Sun, J; Xu, N; Yang, L; Yang, R; Zhang, Z; Zhou, W	1
Liu, Y; Ma, R; Song, L; Xu, Y; Yao, D; Zhang, D; Zhou, H	1
Arad, M; Aravot, D; Hochhauser, E; Kornwoski, R; Nudelman, V; Peterson, SJ; Shainberg, A; Waldman, M; Zemel, R	1
Chhabra, KH; Lazartigues, E; Pedersen, KB; Speth, RC; Xia, H	1
Gong, X; Li, G; Li, Y; Song, Y; Yuan, L	1
Benigni, A; Buelli, S; Gagliardini, E; Longaretti, L; Macconi, D; Morigi, M; Perico, L; Perico, N; Remuzzi, G; Rizzo, P; Tomasoni, S; Zoja, C	1
Chen, M; Gao, H; Liu, Y; Xie, CG; Zhuang, C	1
Auger, C; Kang, M; Kim, KR; Lee, JO; Oak, MH; Park, DH; Schini-Kerth, VB	1
Batlle, D; Burns, KD; Garcia-Halpin, L; Maier, C; Sowers, K; Wysocki, J; Ye, M	1
Chen, JR; Wu, LY; Yang, HY; Yeh, WJ	1
Huang, Y; Lau, CW; Lau, YS; Liu, J; Murugan, D; Mustafa, MR; Tian, XY; Zhang, Y	1
Crisóstomo, J; Matafome, P; Pereira, P; Rodrigues, L; Santos-Silva, D; Seiça, R; Sena, C	1
D'Angelo, A; Derosa, G; Fogari, R; Gualtierotti, R; Lazzari, P; Mugellini, A; Zoppi, A	1
Brouns, AE; Brouwers, O; Daniels, A; Derks, WJ; Janssen, BJ; Munts, C; Schalkwijk, CG; van Bilsen, M; van der Vusse, GJ; van Nieuwenhoven, FA	1
Burghi, V; Dominici, FP; Giani, JF; Muñoz, MC	1
Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K	1
Bédat, B; Böni-Schnetzler, M; Donath, MY; Dror, E; Jehle, AW; Kampe, K; Kerr-Conte, J; Pattou, F; Plutino, Y; Sauter, NS; Thienel, C; Timper, K; Traub, S	1
Cinar, R; Earley, BJ; Godlewski, G; Jourdan, T; Ju, C; Kunos, G; Liu, J; Liu, Z; Pacher, P; Rosenberg, AZ; Szanda, G; Tam, J	1
Cai, H; Youn, JY; Zhou, J	1
Cismowski, MJ; Galantowicz, ML; Husarek, KE; Katz, PS; Lucchesi, PA; Trask, AJ	1
Christiansen, JS; Dejgaard, A; Frøkiaer, J; Goetze, JP; Holst, JJ; Jonassen, T; Madsen, B; Pedersen, M; Rittig, S; Skov, J	1
Derscheid, R; Fuller, KNZ; Koh, GY; Leow, SE; Reed, L; Rowling, MJ; Schalinske, KL; Valentine, RJ; Wisecup, E	1
Cheng, YL; Wang, WN; Xu, HZ; Xu, ZG; Zhang, YY	1
Böhm, M; Dhein, S; Hohl, M; Kabiri, M; Linz, D; Reil, JC; Ruf, S; Sadowski, T; Schotten, U; Verheule, S; Wohlfart, P	1
Al-Salami, H; Elahy, M; Lam, V; Mamo, JC; Mooranian, A; Negrulj, R; Takechi, R	1
Abbate, M; Aparicio, C; Cannata, A; Carrara, F; Diadei, O; Ferrari, S; Fontana, L; Martinetti, D; Parvanova, A; Perna, A; Petrov Iliev, I; Pisanu, G; Remuzzi, G; Rota, S; Ruggenenti, P; Ruggiero, B; Russo, A; Stucchi, N; Trillini, M	1
Jin, F; Sun, X; Wang, K; Zhang, Z	1
Hida, M; Kobayashi, T; Matsumoto, T; Narimatsu, H; Taguchi, K	1
Burghi, V; Cervino, IA; Dominici, FP; Mazziotta, L; Miquet, JG; Muñoz, MC; Quiroga, DT	1
Hosomi, N; Imanishi, M; Ito, S; Kiyomoto, H; Kobori, H; Konishi, Y; Meda, I; Mori, T; Morikawa, T; Nagai, Y; Nakagawa, T; Nishiyama, A; Okada, N; Okumura, M	1
Bivona, BJ; Feng, Y; Harrison-Bernard, LM; Lazartigues, E; Park, S	1
Fukumoto, M; Ikeda, T; Ishizaki, E; Jin, D; Miyazaki, M; Oku, H; Sakaguchi, M; Sakonjo, H; Sugiyama, T; Takai, S	1
Lee, JH; Palaia, T; Ragolia, L	1
Evans, JF; Lee, JH; Ragolia, L	1
Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S	1
Elased, KM; Irigoyen, MC; Kanakamedala, K; Morris, M; Senador, D	1
Chu, KY; Leung, PS	1
Ishida, K; Kamata, K; Kobayashi, T; Matsumoto, T; Nakayama, N	1
Endo, K; Koide, N; Miyashita, Y; Murano, T; Ohira, M; Oyama, T; Saiki, A; Shirai, K; Watanabe, H	1
Brillante, DG; Brillante, RE; Howes, LG; O'Sullivan, AJ	1
Hayashi, T; Takai, S; Yamashita, C	1
Baklanova, NA; Belenkov, IuN; Bolotina, MG; Lapina, IuV; Mareev, VIu; Masenko, VP; Narusov, OIu; Shestakova, MV	1
Bivona, BJ; Chappell, MC; Harrison-Bernard, LM; Kobori, H; Lazartigues, E; Park, S; Seth, DM	1
Blinder, Y; Guzik, TJ; Harrison, DG; Iwakura, Y; Lob, HE; Madhur, MS; McCann, LA	1
Au, CL; Chen, ZY; Huang, Y; Lee, HK; Ng, CF; Tian, XY; Wong, WT; Xu, A; Yao, X	1
Cheng, Q; Leung, PS	1
Bilan, VP; Jackson, EK; Tofovic, DS	1
Cha, DR; Kang, YS; Ko, GJ; Lee, MH; Song, HK	1
Endo, K; Koide, N; Miyashita, Y; Murano, T; Ohira, M; Oyama, T; Saiki, A; Shirai, K	1
Cao, W; Ko, SH; Liu, Z	1
Hara, T; Hitomi, H; Ihara, G; Ito, S; Kiyomoto, H; Kobori, H; Kohno, M; Mori, T; Nagai, Y; Nakano, D; Nishiyama, A; Ohashi, N; Pelisch, N	1
Glassock, RJ	1
Chrousos, GP; Katsilambros, N; Kouskouni, E; Margeli, A; Mastorakos, G; Papassotiriou, I; Pavlatou, MG; Tentolouris, N	1
Chrissobolis, S; Drummond, GR; Kemp-Harper, BK; Miller, AA; Sobey, CG	1
Cai, L; Guo, QY; Li, B; Liu, N; Ma, FZ; Miao, LN; Xu, ZG	1
Aoki, T; Gohda, T; Hagiwara, S; Ihm, CG; Ishikawa, Y; Jeong, KH; Lee, SH; Lee, TW; Lim, SJ; Moon, JY; Murakoshi, M; Ohara, I; Tanimoto, M; Tomino, Y; Yamazaki, T	1
Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K; Takenouchi, Y	1
Bachmann, MF; Jennings, GT	1
Kamata, K; Kobayashi, T; Matsumoto, T; Nemoto, S; Taguchi, K	1
Attia, J; Ingsathit, A; Lertrattananon, D; Ngarmukos, C; Thakkinstian, A; Vejakama, P	1
Bornstein, SR; Goettsch, C; Graessler, J; Kopprasch, S; Saha, S; Schwarz, PE	1
Fujisawa, G; Iwazu, Y; Kimura, M; Kobayashi, E; Kobayashi, T; Kusano, E; Masuda, T; Murakami, T; Muto, S; Nonaka-Sarukawa, M; Sasaki, N; Shimada, K; Shinohara, M; Watanabe, Y	1
Horiuchi, M; Jing, F; Mogi, M	1
Kamata, K; Kobayashi, T; Matsumoto, T; Taguchi, K	1
Henriksen, EJ; Prasannarong, M	1
Fan, YY; Hitomi, H; Kitada, K; Kobori, H; Lei, B; Masaki, T; Mori, H; Nakano, D; Nishiyama, A	1
Kusumoto, K	1
Haji, AA; Kaiser, A; Li, X; Parhat, K; Wei, YY; Yan, D	1
Araki, E; Motoshima, H	1
Bivona, BJ; de Garavilla, L; Ford, SM; Harrison-Bernard, LM; Kobori, H; Park, S; Xu, S	1
Bloch, W; Brixius, K; Reuter, H; Schwinger, RH; Streit, U; Wahlers, T	1
Fan, YY; Hitomi, H; Huang, W; Kobori, H; Li, P; Masaki, T; Mori, H; Nakano, D; Nishiyama, A; Sun, YX; Zhang, L; Zhi, N; Zhu, B	1
Devonald, MA; Karet, FE	1
Hattori, Y; Jesmin, S; Kitabatake, A; Mowa, CN; Sakuma, I	1
Goto, A	1
Anguita Sánchez, M	1
Luño, J; Ruilope, LM	1
Engeli, S; Gorzelniak, K; Janke, J; Luft, FC; Sharma, AM	1
Diamond, T; Howes, LG; Manwaring, P; Phoon, S	1
Fujimura, A; Harada, K; Ohmori, M	1
Bernadet-Monrozies, P; Durand, D; Kamar, N; Rostaing, L	1
Ajayi, AA; Cory, J; Hayes, BE; Hercule, H; Oyekan, AO	1
Dikow, R; Eberhard, R	1
Gaede, P; Jensen, GV; Larsen, N; Parving, HH; Pedersen, O; Vedel, P	1
Carswell, CI; Goa, KL	1
Scholey, JW	1
Camussi, G; Deferrari, G; Doublier, S; Lupia, E; Ruotsalainen, V; Salvidio, G; Verzola, D	1
Berl, T; Drury, PL; Esmatjes, E; Goldhaber, SZ; Hricik, D; Hunsicker, LG; Lewis, EJ; Lewis, JB; Locatelli, F; Parikh, CR; Pfeffer, MA; Porush, JG; Raz, I; Rouleau, JL; Vanhille, P; Wiegmann, TB; Wolfe, BM	1
Hayward, RA; Vijan, S	1
Blumenstein, M; Dietrich, W	1
Mogyorósi, A; Sonkodi, S	1
Mohanram, A; Toto, RD	1
Moskowitz, DW	1
Gaede, PH; Jensen, GV; Jepsen, PV; Larsen, JN; Parving, HH; Pedersen, OB	1
de Jong-van den Berg, LT; de Zeeuw, D; Kruidhof, H; Postma, MJ	1
Hattori, Y; Jesmin, S; Kitabatake, A; Sakuma, I	1
Andersen, S; Bröchner-Mortensen, J; Parving, HH	1
Bramlage, P; Dikow, R; Kirch, W; Lehnert, H; Pittrow, D; Ritz, E; Wittchen, HU	1
Ruilope, LM; Segura, J	1
Frohlich, ED; Sowers, JR	1
Batlle, D; LaPointe, MS; Naaz, P; Salabat, MR; Wysocki, J; Ye, M	1
Croom, KF; Curran, MP; Goa, KL; Perry, CM	1
Unger, T; Zimmermann, M	1
McInnes, GT	1
Coyle, JD; Gardner, SF; White, CM	1
Epstein, BJ	1
Austin, C; Bermann, G; Heagerty, AM; Izzard, A; Malik, RA; Schofield, IJ	1
Abe, Y; Kimura, S; Kiyomoto, H; Kobori, H; Kohno, M; Miyata, K; Miyatake, A; Nagai, Y; Nishiyama, A; Ozawa, Y; Shokoji, T; Yao, L; Yukimura, T	1
Gaciong, Z	1
Leiter, LA; Lewanczuk, RZ	1
Howes, JB; Howes, LG; Lowy, A; Tran, D	1
Battegay, E; Zeller, A	1
Inoguchi, T; Kobayashi, K; Maeda, Y; Nakayama, M; Nawata, H; Sasaki, S; Sawada, F; Sonoda, N; Sonta, T; Sumimoto, H; Tsubouchi, H	1
Hu, G; Xue, C; Yang, J	1
Boner, G; Brenner, BM; Cooper, ME; Crow, RS; de Zeeuw, D; Dickson, T; Kowey, PR; McCarroll, K; Parving, HH; Shahinfar, S	1
Nagaria, AM; Reddy, S; Savin, VJ; Sharma, M; Sharma, R; Wiegmann, TB	1
Boasquevisque, EM; de Lourdes Rodrigues, M; Francischetti, EA; Genelhu, V; Ismerim, VL; Matos, JP	1
Cooper, ME; Thomas, MC; Tikellis, C	1
Hashimoto, N; Saito, Y; Seki, N; Suzuki, Y; Yagui, K	1
Howes, LG	1
Matsumoto, M; Suzuki, S; Tahara, T; Taniguchi, K; Yabuki, A	1
Horiuchi, M; Iwai, M; Mogi, M	1
Hirata, A; Igarashi, M; Kadomoto, Y; Tominaga, M	1
Barit, D; Cooper, ME; Giunti, S	1
Adam, C; Brabender, J; Frank, KF; Grönke, S; Müller-Ehmsen, J; Reuter, H; Schwinger, RH; Zobel, C	1
Eguchi, S; Suzuki, H	1
Vinson, GP	1
Savoia, C; Schiffrin, EL; Touyz, RM; Volpe, M	1
Leung, PS	1
Savoia, C; Schiffrin, EL	1
Ageno, W; Dentali, F; Romualdi, E	1
Huang, Y; Lau, CW; Lin, SG; Yu, XY; Yung, LM; Zhong, JC	1
Brenner, BM; Cooper, ME; de Zeeuw, D; Eijkelkamp, WB; Gleim, GW; Keane, WF; Parving, HH; Remuzzi, G; Shahinfar, S; Weir, MR; Zhang, Z	1
Fujimoto, N; Matsumoto, T; Nishii, H; Nomura, M; Ozaki, Y	1
Goralski, KB; Sinal, CJ	1
Balogh, Z; Fóris, G; Fülöp, P; Kassai, A; Kosztáczky, B; Paragh, G; Seres, I; Varga, Z	1
Henriksen, EJ	1
Cooper, SA; Habibi, J; Lastra, G; Manrique, C; Sowers, JR; Stas, S; Wei, Y; Whaley-Connell, A	1
Morris, AD; Sharman, DC; Struthers, AD	1
Petkow-Dimitrow, P	1
Boyle, PJ	1
Miller, AG; Wilkinson-Berka, JL	1
Feliers, D; Lee, MJ; Mariappan, MM; Sataranatarajan, K	1
Goncharov, NP; Il'in, AV; Katsaia, GV; Koshel', LV; Malysheva, NM; Nikankina, LV; Shamkhlova, MSh; Shestakova, MV; Trubitsyna, NP	1
Davies, J; George, J; Morris, AD; Rajendra, NS; Struthers, AD; Swaminathan, K	1
Lee, JH; Ragolia, L; Xia, S	1
Dawson, D; Denver, E; Foyle, WJ; Pinkney, J; Sampson, MJ; Yudkin, JS	1
Connell, JM; Donnelly, R; Elliott, HL; Morris, AD; Petrie, JR; Small, M; Ueda, S	1
Harker, CT; Kasiske, BL; Katz, SA; Keane, WF; O'Donnell, MP	1
Beretta-Piccoli, C; Cusi, D; Elshater-Zanetti, F; Shaw, S; Weidmann, P	1
Donnely, R; Morris, AD	1
Leese, GP; Vora, JP	1
Bensaoula, T; Eichberg, J; Ottlecz, A; Peterson, RG	1
Cipollina, MR; Di Virgilio, F; Duner, E; Nosadini, R; Trevisan, M; Trevisan, R	1
Schiffrin, EL; Touyz, RM	1
Cipollina, MR; Crepaldi, G; Di Virgilio, F; Duner, E; Nosadini, R; Trevisan, R	1
Adèr, HJ; Donker, AJ; Gans, RO; Spooren, PF; Vermes, I	1
Daher, A; Diamond, T; Howes, LG; Lykos, D; Morris, R; Sundaresan, P	1
Akishita, M; Eto, M; Hashimoto, M; Kim, S; Kozaki, K; Nagano, K; Ouchi, Y; Sudo, N; Toba, K; Watanabe, M; Yoo, HJ; Yoshizumi, M	1
Allan, DR; De'Oliveira, JM; Fisher, ND; Hollenberg, NK; McKnight, JA; Price, DA; Williams, GH	1
Hamaguchi, A; Iwao, H; Kim, S; Miura, K; Wanibuchi, H; Yamanaka, S	1
Bahrmann, P; Bergis, K; Fliser, D; Franek, E; Keller, C; Ritz, E; Schreckling, H	1
Elliott, HL; Hilditch, TE; McConnell, J; Minamisawa, K; Morris, AD; Petrie, JR; Small, M	1
Abbott, D; Diamond, T; Howes, LG; Manwaring, P; Morfis, L; Williams, S	1
De'Oliveira, JM; Fisher, ND; Hollenberg, NK; Price, DA; Williams, GH	1
Baba, T; Gohda, T; Haneda, M; Kikkawa, R; Makita, Y; Shike, T; Tomino, Y; Watanabe, T; Yoshida, H	1
Carlson, SH; Shelton, J; White, CR; Wyss, JM	1
Gavras, H	1
Burns, KD	1
de La Sierra, A; Ruilope, LM	1
Anversa, P; Chimenti, C; Frustaci, A; Jakoniuk, I; Kajstura, J; Leri, A; Maseri, A; Nadal-Ginard, B	1
Blüher, M; Kratzsch, J; Paschke, R	1
Imura, Y; Matsuo, T; Nagano-Tsuge, H; Naka, T; Noda, M; Ohta, M; Sekiguchi, M; Shibouta, Y	1
El Khyat, Z; El Sayed, A; Ibrahim, S; Nicola, W; Salah, A; Sidhom, G	1
Mogensen, CE	1
Brenner, BM; Cooper, ME; de Zeeuw, D; Keane, WF; Mitch, WE; Parving, HH; Remuzzi, G; Shahinfar, S; Snapinn, SM; Zhang, Z	1
Andersen, S; Arner, P; Brøchner-Mortensen, J; Gomis, R; Lehnert, H; Parving, HH	1
Atkins, RC; Cooper, ME; Gilbert, RE; Jerums, G	1
Shimoni, Y	1
Beevers, DG; Lip, GY	1
Okada, M; Takemura, T; Yanagida, H; Yoshioka, K	1
Attvall, S; Nilsson, P	1
Arner, P	1
Allen, TJ; Baxter, AL; Casley, DJ; Cooper, ME; Houlihan, CA; Jerums, G; Panangiotopoulos, S	1
Boner, G; Erman, A; van Dijk, DJ	1
Easthope, SE; Jarvis, B	1
Draganov, B; Holdaas, H; Høieggen, A; Jenssen, T; Os, I; Stenehjem, A	1
Ishibashi, M; Kamoi, K; Yamaji, T	1
Balsano, F; Bellini, C; Bravi, C; De Angelis, C; De Mattia, G; Ferri, C; Giarrizzo, C; Laurenti, O; Santucci, A	1
Azukizawa, S; Iwasaki, R; Kaneko, M; Kigoshi, T; Morimoto, S; Nakano, S; Uchida, K	1
Corry, D; Trujillo, A; Tuck, M	1
Iwasaki, R; Kigoshi, T; Morimoto, S; Uchida, K	1
Barrett, J; Eggena, P; Trujillo, A; Tuck, M	1
Yaginuma, K	1

Reviews

60 review(s) available for angiotensin ii and Diabetes Mellitus, Type 2

Article	Year
Does the Naked Emperor Parable Apply to Current Perceptions of the Contribution of Renin Angiotensin System Inhibition in Hypertension? Current hypertension reports, 2022, Volume: 24, Issue:12 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Diabetes Mellitus, Type 2; Humans; Hypertension; Renin; Renin-Angiotensin System	2022
Cardiovascular Protection with a Long-Acting GLP-1 Receptor Agonist Liraglutide: An Experimental Update. Molecules (Basel, Switzerland), 2023, Feb-01, Volume: 28, Issue:3 Topics: Angiotensin II; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucagon-Like Peptide-1 Receptor; Heart Failure; Humans; Hypertension; Hypoglycemic Agents; Liraglutide	2023
Impact of the gut microbiota on angiotensin Ⅱ-related disorders and its mechanisms. Biochemical pharmacology, 2023, Volume: 214 Topics: Angiotensin II; COVID-19; Diabetes Mellitus, Type 2; Disease Progression; Gastrointestinal Microbiome; Humans; Peptidyl-Dipeptidase A; Renin-Angiotensin System	2023
Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics. Hypertension (Dallas, Tex. : 1979), 2023, Volume: 80, Issue:11 Topics: Angiotensin II; Angiotensinogen; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Hypertension; Renin-Angiotensin System; RNA, Small Interfering	2023
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Immunologic and endocrine functions of adipose tissue: implications for kidney disease. Nature reviews. Nephrology, 2018, Volume: 14, Issue:2 Topics: Adipokines; Adiponectin; Adipose Tissue; AMP-Activated Protein Kinases; Angiotensin II; Angiotensinogen; Ceramidases; Diabetes Mellitus, Type 2; Humans; Inflammation; Kidney Diseases; Leptin; Macrophages; Obesity; Receptors, Adiponectin; Signal Transduction	2018
Changes in the pancreas caused by different types of hypertension. Acta biochimica Polonica, 2017, Volume: 64, Issue:4 Topics: Angiotensin II; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin Resistance; Pancreas	2017
Modulation of the action of insulin by angiotensin-(1-7). Clinical science (London, England : 1979), 2014, Volume: 126, Issue:9 Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Peptide Fragments; Peptidyl-Dipeptidase A; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptors, G-Protein-Coupled; Renin-Angiotensin System; Signal Transduction	2014
Angiotensin II in type 2 diabetes mellitus. Current protein & peptide science, 2009, Volume: 10, Issue:1 Topics: Angiotensin II; Animals; Diabetes Mellitus, Type 2; Humans; Insulin Resistance	2009
Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. Current vascular pharmacology, 2010, Volume: 8, Issue:2 Topics: Aldosterone; Angiotensin II; Animals; Cardiovascular Diseases; Chymases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Humans; Oxidative Stress; Renin-Angiotensin System	2010
The novel roles of glucagon-like peptide-1, angiotensin II, and vitamin D in islet function. Advances in experimental medicine and biology, 2010, Volume: 654 Topics: Angiotensin II; Angiotensins; Animals; Blood Pressure; Cell Nucleus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Humans; Islets of Langerhans; Mice; Models, Biological; Peptides; Vitamin D	2010
Hypertension management and microvascular insulin resistance in diabetes. Current hypertension reports, 2010, Volume: 12, Issue:4 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Diabetes Mellitus, Type 2; Humans; Hypertension; Inflammation; Insulin Resistance; Microcirculation; Microvessels; Nitric Oxide Synthase Type III; Oxidative Stress; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Signal Transduction	2010
Uremia (end-stage renal disease): how cost-effective are preventive strategies? Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation, 2010, Volume: 20, Issue:5 Suppl Topics: Angiotensin II; Antihypertensive Agents; Cost-Benefit Analysis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Failure, Chronic; Mass Screening; Proteinuria	2010
Oxidative stress and endothelial dysfunction in cerebrovascular disease. Frontiers in bioscience (Landmark edition), 2011, 01-01, Volume: 16, Issue:5 Topics: Alzheimer Disease; Amidohydrolases; Angiotensin II; Animals; Brain Ischemia; Cerebrovascular Disorders; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Humans; Hypertension; Mitochondria; Nitric Oxide; Oxidative Stress; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Prostaglandin-Endoperoxide Synthases; Reperfusion Injury; Stroke; Subarachnoid Hemorrhage; Superoxide Dismutase	2011
Therapeutic vaccines for chronic diseases: successes and technical challenges. Philosophical transactions of the Royal Society of London. Series B, Biological sciences, 2011, Oct-12, Volume: 366, Issue:1579 Topics: Angiotensin II; Animals; Antibodies; Antibody Formation; Antihypertensive Agents; Chronic Disease; Diabetes Mellitus, Type 2; Humans; Hypertension; Interleukin-1beta; Mice; Nicotine; Risk Factors; Smoking; Smoking Cessation; Vaccination; Vaccines; Vaccines, Virus-Like Particle	2011
Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia, 2012, Volume: 55, Issue:3 Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Kidney Failure, Chronic; Middle Aged; Randomized Controlled Trials as Topic; Renin-Angiotensin System	2012
Role of renin-angiotensin-aldosterone system in adipose tissue dysfunction. Molecular and cellular endocrinology, 2013, Sep-25, Volume: 378, Issue:1-2 Topics: Adipocytes; Adipose Tissue; Angiotensin II; Animals; Cell Differentiation; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Mineralocorticoid; Renin-Angiotensin System; Signal Transduction	2013
The role of the renin-angiotensin system in the development of insulin resistance in skeletal muscle. Molecular and cellular endocrinology, 2013, Sep-25, Volume: 378, Issue:1-2 Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Biological Transport, Active; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin Resistance; Insulin-Secreting Cells; Muscle, Skeletal; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System	2013
[In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan]. Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2012, Volume: 139, Issue:6 Topics: Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Benzimidazoles; Blood Pressure; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypertension; Insulin Resistance; Obesity; Oxadiazoles	2012
[RAAS and insulin resistance]. Nihon rinsho. Japanese journal of clinical medicine, 2012, Volume: 70, Issue:9 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Diabetes Mellitus, Type 2; Humans; Insulin Resistance; Oxidative Stress; Renin-Angiotensin System	2012
Targeting the renin-angiotensin system in patients with renal disease. Journal of the Royal Society of Medicine, 2002, Volume: 95, Issue:8 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Contraindications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Kidney Diseases; Proteinuria; Risk Factors; Vasoconstrictor Agents	2002
[Prevention and treatment of congestive heart failure in diabetic patients]. Revista espanola de cardiologia, 2002, Volume: 55, Issue:10 Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Carbazoles; Cardiotonic Agents; Carvedilol; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Lisinopril; Male; Meta-Analysis as Topic; Metoprolol; Prognosis; Propanolamines; Risk Factors; Time Factors	2002
Angiotensin blockade in type 2 diabetic renal disease. Kidney international. Supplement, 2002, Issue:82 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Evidence-Based Medicine; Humans; Renin-Angiotensin System; Treatment Outcome	2002
[The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure]. Presse medicale (Paris, France : 1983), 2002, Nov-09, Volume: 31, Issue:36 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Clinical Trials as Topic; Cohort Studies; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Endothelins; Hemodynamics; Humans; Hypertension; Indoles; Irbesartan; Kidney; Kidney Failure, Chronic; Proteinuria; Randomized Controlled Trials as Topic; Receptors, Angiotensin; Renin-Angiotensin System; Tetrazoles; Verapamil	2002
Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes. Annals of medicine, 2002, Volume: 34, Issue:7-8 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension, Renal; Irbesartan; Losartan; Renin-Angiotensin System; Tetrazoles	2002
Losartan in diabetic nephropathy. Drugs, 2003, Volume: 63, Issue:4 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Losartan; Receptor, Angiotensin, Type 1	2003
Angiotensin II and the glomerulus: focus on diabetic kidney disease. Current hypertension reports, 2003, Volume: 5, Issue:2 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Humans; Kidney Glomerulus; Renin-Angiotensin System	2003
Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Annals of internal medicine, 2003, Apr-01, Volume: 138, Issue:7 Topics: Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzothiadiazines; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diuretics; Evidence-Based Medicine; Humans; Hypertension; Randomized Controlled Trials as Topic; Sodium Chloride Symporter Inhibitors	2003
Treatment of diabetic nephropathy with angiotensin II blockers. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2003, Volume: 18 Suppl 5 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Female; Humans; Male; Prognosis; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Assessment; Severity of Illness Index; Treatment Outcome	2003
Outcome studies in diabetic nephropathy. Seminars in nephrology, 2003, Volume: 23, Issue:3 Topics: Albuminuria; Anemia; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hyperglycemia; Hyperlipidemias; Hypertension, Renal; Irbesartan; Kidney Failure, Chronic; Male; Outcome Assessment, Health Care; Proteinuria; Renin-Angiotensin System; Risk Factors; Smoking; Tetrazoles	2003
Pathophysiologic implications of angiotensin I-converting enzyme as a mechanosensor: diabetes. Diabetes technology & therapeutics, 2003, Volume: 5, Issue:2 Topics: Aging; Angiotensin II; Animals; Blood Vessels; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Diabetic Retinopathy; Heart Diseases; Humans; Insulin Resistance; Mechanoreceptors; Peptidyl-Dipeptidase A	2003
Pharmacoeconomic aspects of losartan treatment to delay progression of renal disease in patients with Type 2 diabetes. Expert opinion on pharmacotherapy, 2003, Volume: 4, Issue:9 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Health Care Costs; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Tetrazoles; Treatment Outcome	2003
Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. Clinical therapeutics, 2003, Volume: 25, Issue:12 Topics: Albuminuria; Amlodipine; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Kidney Failure, Chronic; Losartan; Proteinuria; Tetrazoles	2003
Insulin and insulin resistance: impact on blood pressure and cardiovascular disease. The Medical clinics of North America, 2004, Volume: 88, Issue:1 Topics: Angiotensin II; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypertension; Insulin; Insulin Resistance; Obesity; Risk Factors	2004
Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy. Drugs, 2004, Volume: 64, Issue:9 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension; Irbesartan; Randomized Controlled Trials as Topic; Tetrazoles	2004
How important is optimal blood pressure control? Clinical therapeutics, 2004, Volume: 26 Suppl A Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Humans; Hypertension; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risk Factors	2004
The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:10 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Kidney Diseases	2004
[New therapeutic options in renal diseases--hypotensive therapy]. Polskie Archiwum Medycyny Wewnetrznej, 2004, Volume: 112 Spec No Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension, Renal; Kidney Failure, Chronic; Risk Factors	2004
Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition. American journal of hypertension, 2005, Volume: 18, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Humans; Inflammation; Insulin Resistance; Metabolic Syndrome; Obesity; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System	2005
[Angiotensin II receptor blockers--evidence along the cardiovascular continuum]. Praxis, 2005, Apr-13, Volume: 94, Issue:15 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Albuminuria; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dogs; Drug Therapy, Combination; Female; Heart Failure; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Myocardial Infarction; Placebos; Rabbits; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors; Stroke; Tetrazoles; Time Factors	2005
Chronically increased intrarenal angiotensin II causes nephropathy in an animal model of type 2 diabetes. Frontiers in bioscience : a journal and virtual library, 2006, Jan-01, Volume: 11 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Animals, Genetically Modified; Blood Pressure; Chromatography; Collagen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Fibronectins; Glucose; Hyperglycemia; Immunoblotting; Insulin; Insulin Resistance; Kidney; Male; Models, Statistical; Obesity; Proteinuria; Radioimmunoassay; Rats; Rats, Zucker; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation	2006
Role of the renin-angiotensin system in the endocrine pancreas: implications for the development of diabetes. The international journal of biochemistry & cell biology, 2006, Volume: 38, Issue:5-6 Topics: Angiotensin I; Angiotensin II; Angiotensinogen; Animals; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Fibrosis; Humans; Hyperglycemia; Hypoglycemia; Islets of Langerhans; Pancreas; Peptidyl-Dipeptidase A; PPAR gamma; Receptors, Angiotensin; Renin; Renin-Angiotensin System	2006
The effects of lipid-lowering drug therapy on cardiovascular responsiveness in type 2 diabetic patients. Diabetes, obesity & metabolism, 2006, Volume: 8, Issue:1 Topics: Angiotensin II; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Endothelium, Vascular; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intravenous; Lipoproteins; Norepinephrine; Vasodilation	2006
Signaling crosstalk angiotensin II receptor subtypes and insulin. Endocrine journal, 2006, Volume: 53, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucose; Humans; Hypertension; Insulin; Insulin Resistance; Mice; Models, Animal; Rats; Receptor Cross-Talk; Receptors, Angiotensin; Risk Factors; Signal Transduction	2006
Diabetic nephropathy: from mechanisms to rational therapies. Minerva medica, 2006, Volume: 97, Issue:3 Topics: Angiotensin II; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Endothelin-1; Glycation End Products, Advanced; Humans; Hypertension; Protein Kinase C; Urotensins	2006
Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2007, Volume: 24, Issue:2 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Heart Failure; Humans; Hypertension; Insulin Resistance; Islets of Langerhans; Renin-Angiotensin System; Vasoconstrictor Agents	2007
Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clinical science (London, England : 1979), 2007, Volume: 112, Issue:7 Topics: Aldosterone; Angiotensin II; Cell Adhesion Molecules; Cytokines; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypertension; NF-kappa B; Renin-Angiotensin System; Vasculitis	2007
Type 2 diabetes and cardiovascular disease: getting to the fat of the matter. Canadian journal of physiology and pharmacology, 2007, Volume: 85, Issue:1 Topics: Adiponectin; Adipose Tissue; Angiotensin II; Animals; Cardiovascular Diseases; Complement Activation; Complement C3a; Complement Factor D; Cytokines; Diabetes Mellitus, Type 2; Fibrinolysis; Humans; Inflammation; Insulin Resistance; Interleukin-6; Leptin; Nicotinamide Phosphoribosyltransferase; Obesity; Plasminogen Activator Inhibitor 1; Renin-Angiotensin System; Resistin; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Risk Factors; Tumor Necrosis Factor-alpha	2007
Improvement of insulin sensitivity by antagonism of the renin-angiotensin system. American journal of physiology. Regulatory, integrative and comparative physiology, 2007, Volume: 293, Issue:3 Topics: Adipose Tissue; Angiotensin II; Child; Diabetes Mellitus, Type 2; Glucose; Humans; Insulin Resistance; Metabolic Syndrome; Muscle, Skeletal; Renin-Angiotensin System	2007
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. American journal of physiology. Heart and circulatory physiology, 2007, Volume: 293, Issue:4 Topics: Angiotensin II; Animals; Cardiovascular Diseases; Chronic Disease; Diabetes Mellitus, Type 2; Endothelium, Vascular; Humans; Hypertension; Insulin; Insulin Resistance; Insulin-Like Growth Factor I; Kidney Diseases; Metabolic Syndrome; Mineralocorticoids; Muscle, Skeletal; Myocardium; Oxidative Stress; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk Factors; Signal Transduction	2007
[New therapeutic targets for ACE inhibitors and angiotensin receptor blockers]. Polskie Archiwum Medycyny Wewnetrznej, 2007, Volume: 117, Issue:4 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypertension; Losartan; Metabolic Syndrome; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Risk Reduction Behavior; Telmisartan; Treatment Outcome	2007
Diabetes mellitus and macrovascular disease: mechanisms and mediators. The American journal of medicine, 2007, Volume: 120, Issue:9 Suppl 2 Topics: Adiponectin; Angiotensin II; Animals; Atherosclerosis; Blood Coagulation; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Insulin Resistance; Peroxisome Proliferator-Activated Receptors	2007
Update on the treatment of diabetic retinopathy. TheScientificWorldJournal, 2008, Feb-06, Volume: 8 Topics: Adrenal Cortex Hormones; Aldehyde Reductase; Angiotensin II; Antihypertensive Agents; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dyslipidemias; Enzyme Inhibitors; Glycation End Products, Advanced; Human Growth Hormone; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insulin; Laser Coagulation; Protein Kinase C; Vascular Endothelial Growth Factor A; Vitamin E	2008
Clinical review 79: Angiotensin II: an insulin-sensitizing vasoactive hormone? The Journal of clinical endocrinology and metabolism, 1996, Volume: 81, Issue:4 Topics: Angiotensin II; Animals; Blood Vessels; Diabetes Mellitus, Type 2; Heart; Hemodynamics; Humans; Insulin; Insulin Resistance; Kidney; Regional Blood Flow; Renin-Angiotensin System; Vasoconstrictor Agents	1996
The management of hypertension in diabetes: with special reference to diabetic kidney disease. Diabetic medicine : a journal of the British Diabetic Association, 1996, Volume: 13, Issue:5 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Catecholamines; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Retinopathy; Glomerular Filtration Rate; Hypertension	1996
Angiotensin II and its receptors in the diabetic kidney. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2000, Volume: 36, Issue:3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Bacterial Agents; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Kidney; Kidney Glomerulus; Mice; Peptidyl-Dipeptidase A; Proteinuria; Rats; Receptors, Angiotensin; Renin; Renin-Angiotensin System; RNA, Messenger; Streptozocin	2000
Treatment of hypertension in diabetes mellitus. Current hypertension reports, 2000, Volume: 2, Issue:3 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Arteriosclerosis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypertension; Kidney Diseases; Myocardial Infarction; Placebos; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Risk Factors	2000
The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy. Journal of human hypertension, 2001, Volume: 15, Issue:12 Topics: Aged; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Irbesartan; Losartan; Male; Middle Aged; Primary Prevention; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Tetrazoles; Treatment Outcome	2001
Candesartan cilexetil: an update of its use in essential hypertension. Drugs, 2002, Volume: 62, Issue:8 Topics: Adsorption; Age Factors; Aged; Angiotensin II; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Black People; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypertension; Hypertrophy, Left Ventricular; Kidney; Renal Insufficiency; Tetrazoles; Treatment Outcome	2002
[Type 2 diabetes and nephropathy--new studies, new treatment strategies?]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2002, Apr-10, Volume: 122, Issue:9 Topics: Amlodipine; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Losartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System	2002

Trials

40 trial(s) available for angiotensin ii and Diabetes Mellitus, Type 2

Article	Year
Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants. The Journal of clinical endocrinology and metabolism, 2022, 05-17, Volume: 107, Issue:6 Topics: Aldosterone; Angiotensin II; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Natriuresis; Recombinant Fusion Proteins; Renin	2022
Progressive resistance training ameliorates deteriorating cardiac autonomic dysfunction, subclinical inflammation and endothelial dysfunction in type 2 diabetes mellitus: A randomized control trial. Diabetes & metabolic syndrome, 2023, Volume: 17, Issue:5 Topics: Angiotensin II; Autonomic Nervous System Diseases; Biomarkers; Diabetes Mellitus, Type 2; Humans; Inflammation; Resistance Training; Vascular Diseases	2023
Changes of aldosterone levels in patients with type 2 diabetes complicated by moderate to severe obstructive sleep apnea-hypopnea syndrome before and after treatment with continuous positive airway pressure. The Journal of international medical research, 2019, Volume: 47, Issue:10 Topics: Aldosterone; Angiotensin II; Case-Control Studies; Continuous Positive Airway Pressure; Diabetes Mellitus, Type 2; Female; Humans; Male; Middle Aged; Renin; Sleep Apnea, Obstructive	2019
Effect of angiotensin II receptor blocker and salt supplementation on short-term blood pressure variability in type 2 diabetes. Journal of human hypertension, 2020, Volume: 34, Issue:2 Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Dietary Supplements; Female; Humans; Hypertension; Renin; Renin-Angiotensin System; Sodium Chloride; Sodium Chloride, Dietary	2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors. Annales medico-psychologiques, 2021, Volume: 179, Issue:2 Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acrylic Resins; Actinobacillus; Acute Disease; Acute Kidney Injury; Adaptor Proteins, Signal Transducing; Adenosine; Adenosine Triphosphate; Administration, Inhalation; Administration, Oral; Adolescent; Adult; Advance Care Planning; Africa, Northern; Age Factors; Aged; Aged, 80 and over; Air Pollutants; Air Pollution; Air Pollution, Indoor; Albendazole; Aluminum Oxide; Anastomosis, Surgical; Ancylostoma; Ancylostomiasis; Androstadienes; Angiogenesis Inhibitors; Angiotensin II; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antibodies, Bispecific; Antibodies, Viral; Anticoagulants; Antihypertensive Agents; Antinematodal Agents; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Antiporters; Antiviral Agents; Apoptosis; Aptamers, Nucleotide; Aromatase Inhibitors; Asian People; Astrocytes; Atrial Fibrillation; Auditory Threshold; Aurora Kinase B; Australia; Autophagy; Autophagy-Related Protein 5; Autotrophic Processes; Bacillus cereus; Bacillus thuringiensis; Bacterial Proteins; Beclin-1; Belgium; Benzene; Benzene Derivatives; Benzhydryl Compounds; beta Catenin; beta-Arrestin 2; Biliary Tract Diseases; Biofilms; Biofuels; Biomarkers; Biomarkers, Tumor; Biomass; Biomechanical Phenomena; Bioreactors; Biosensing Techniques; Biosynthetic Pathways; Bismuth; Blood Platelets; Bone and Bones; Bone Regeneration; Bortezomib; Botulinum Toxins, Type A; Brain; Brain Injuries; Brain Ischemia; Brain Neoplasms; Breast Neoplasms; Breath Tests; Bronchodilator Agents; Calcium Phosphates; Cannabis; Carbon Dioxide; Carbon Isotopes; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cardiac Resynchronization Therapy; Cardiac Resynchronization Therapy Devices; Cardiomyopathies; Cardiovascular Diseases; Cariostatic Agents; Case Managers; Case-Control Studies; Catalysis; Cation Transport Proteins; CD8-Positive T-Lymphocytes; Cecropia Plant; Cell Adhesion; Cell Count; Cell Differentiation; Cell Division; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Self Renewal; Cell Survival; Cells, Cultured; Cellular Reprogramming; Cellulose; Charcoal; Chemical and Drug Induced Liver Injury; Chemical Phenomena; Chemokines; Chemoradiotherapy; Chemoreceptor Cells; Child; Child Abuse; Child, Preschool; China; Chlorogenic Acid; Chloroquine; Chromatography, Gas; Chronic Disease; Clinical Competence; Coated Materials, Biocompatible; Cochlea; Cohort Studies; Color; Comorbidity; Computer Simulation; Computer-Aided Design; Contraception; Contraceptive Agents, Female; Contrast Media; COP-Coated Vesicles; Coronavirus Infections; Cost of Illness; Coturnix; COVID-19; Creatinine; Cross-Over Studies; Cross-Sectional Studies; Culex; Curriculum; Cyclic N-Oxides; Cytokines; Cytoplasm; Cytotoxicity, Immunologic; Cytotoxins; Databases, Factual; Deep Learning; Delivery, Obstetric; Denitrification; Dental Caries; Denture, Complete; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dielectric Spectroscopy; Diet, High-Fat; Dietary Fiber; Disease Models, Animal; Disease Progression; DNA; DNA Copy Number Variations; DNA, Mitochondrial; Dog Diseases; Dogs; Dopaminergic Neurons; Double-Blind Method; Down-Regulation; Doxorubicin; Drug Carriers; Drug Design; Drug Interactions; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Drugs, Chinese Herbal; Dry Powder Inhalers; Dust; E2F1 Transcription Factor; Ecosystem; Education, Nursing; Education, Nursing, Baccalaureate; Electric Impedance; Electricity; Electrocardiography; Electrochemical Techniques; Electrochemistry; Electrodes; Electrophoresis, Polyacrylamide Gel; Endoplasmic Reticulum; Endothelial Cells; Environmental Monitoring; Enzyme Inhibitors; Epithelial Cells; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Estrogen Receptor Modulators; Europe; Evoked Potentials, Auditory, Brain Stem; Exosomes; Feasibility Studies; Female; Ferricyanides; Ferrocyanides; Fibrinogen; Finite Element Analysis; Fistula; Fluorescent Dyes; Fluorides, Topical; Fluorodeoxyglucose F18; Fluticasone; Follow-Up Studies; Food Contamination; Food Microbiology; Foods, Specialized; Forensic Medicine; Frail Elderly; France; Free Radicals; Fresh Water; Fungi; Fungicides, Industrial; Galactosamine; Gastrointestinal Neoplasms; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Frequency; Genetic Predisposition to Disease; Genotype; Gingival Hemorrhage; Glioblastoma; Glioma; Glomerular Filtration Rate; Glomerulosclerosis, Focal Segmental; Glucose; Glucose Transport Proteins, Facilitative; Glucosides; Glutamine; Glycolysis; Gold; GPI-Linked Proteins; Gram-Negative Bacteria; Gram-Positive Bacteria; Graphite; Haplotypes; HCT116 Cells; Healthy Volunteers; Hearing Loss; Heart Failure; Hedgehog Proteins; HEK293 Cells; HeLa Cells; Hemodynamics; Hemorrhage; Hepatocytes; Hippo Signaling Pathway; Histone Deacetylases; Homeostasis; Hospital Mortality; Hospitalization; Humans; Hydantoins; Hydrazines; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Hydroxylamines; Hypoglycemic Agents; Immunity, Innate; Immunoglobulin G; Immunohistochemistry; Immunologic Factors; Immunomodulation; Immunophenotyping; Immunotherapy; Incidence; Indazoles; Indonesia; Infant; Infant, Newborn; Infarction, Middle Cerebral Artery; Inflammation; Injections, Intramuscular; Insecticides; Insulin-Like Growth Factor I; Insurance, Health; Intention to Treat Analysis; Interleukin-1 Receptor-Associated Kinases; Interleukin-6; Intrauterine Devices; Intrauterine Devices, Copper; Iron; Ischemia; Jordan; Keratinocytes; Kidney; Kidney Diseases; Kir5.1 Channel; Klebsiella Infections; Klebsiella pneumoniae; Lab-On-A-Chip Devices; Laparoscopy; Lasers; Lasers, Semiconductor; Lenalidomide; Leptin; Lethal Dose 50; Levonorgestrel; Limit of Detection; Lipid Metabolism; Lipid Metabolism Disorders; Lipogenesis; Lipopolysaccharides; Liquid Biopsy; Liver; Liver Abscess, Pyogenic; Liver Cirrhosis; Liver Diseases; Liver Neoplasms; Longevity; Lung Neoplasms; Luteolin; Lymph Nodes; Lymphocyte Activation; Macaca fascicularis; Macrophages; Mad2 Proteins; Magnetic Resonance Imaging; Male; Mammary Glands, Human; Manganese; Manganese Compounds; MAP Kinase Signaling System; Materials Testing; Maternal Health Services; MCF-7 Cells; Medicaid; Medicine, Chinese Traditional; Melanoma; Membrane Proteins; Mental Health; Mercury; Metal Nanoparticles; Metals, Heavy; Metformin; Methionine Adenosyltransferase; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Knockout; Mice, Nude; Microalgae; Microbial Sensitivity Tests; Microglia; MicroRNAs; Microscopy, Atomic Force; Microscopy, Electron, Scanning; Middle Aged; Mitochondria; Mitochondrial Proteins; Mitral Valve; Mitral Valve Insufficiency; Models, Anatomic; Molecular Structure; Molybdenum; Monocarboxylic Acid Transporters; Moths; MPTP Poisoning; Multigene Family; Multiparametric Magnetic Resonance Imaging; Multiple Myeloma; Muscle, Skeletal; Mutagens; Mutation; Myeloid Cells; Nanocomposites; Nanofibers; Nanomedicine; Nanoparticles; Nanowires; Neoadjuvant Therapy; Neomycin; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasms; Neoplastic Stem Cells; Neostriatum; Neovascularization, Pathologic; Netherlands; Neuromuscular Agents; Neurons; NF-E2-Related Factor 2; NF-kappa B; Nickel; Nitrogen Oxides; Non-alcoholic Fatty Liver Disease; Nucleosides; Nucleotidyltransferases; Nutritional Status; Obesity, Morbid; Ofloxacin; Oils, Volatile; Oligopeptides; Oncogene Protein v-akt; Optical Imaging; Organic Cation Transport Proteins; Organophosphonates; Osteoarthritis; Osteoarthritis, Hip; Osteoarthritis, Knee; Osteoblasts; Osteogenesis; Oxidation-Reduction; Oxidative Stress; Oxides; Oxygen Isotopes; Pancreas; Pancreaticoduodenectomy; Pandemics; Particle Size; Particulate Matter; Patient Acceptance of Health Care; Patient Compliance; PC-3 Cells; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Periodontal Pocket; Periodontitis; Peroxides; Peru; Pest Control, Biological; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Phylogeny; Pilot Projects; Piperidines; Plant Bark; Plant Extracts; Plant Leaves; Plasmids; Platelet Function Tests; Pneumonia, Viral; Podocytes; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Polyethylene Terephthalates; Polymers; Polymorphism, Single Nucleotide; Porosity; Portugal; Positron-Emission Tomography; Postoperative Complications; Postural Balance; Potassium Channels, Inwardly Rectifying; Povidone; Powders; Precancerous Conditions; Precision Medicine; Predictive Value of Tests; Pregnancy; Prenatal Care; Prognosis; Promoter Regions, Genetic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proteasome Inhibitors; Protective Agents; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Psychiatric Nursing; PTEN Phosphohydrolase; Pulmonary Embolism; Pyrimethamine; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Receptors, G-Protein-Coupled; Recombinational DNA Repair; Recovery of Function; Regional Blood Flow; Renal Dialysis; Renin; Renin-Angiotensin System; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Distress Syndrome; Retrospective Studies; Rhodamines; Risk Assessment; Risk Factors; RNA, Long Noncoding; RNA, Messenger; Running; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Salinity; Salmeterol Xinafoate; Sarcoma; Seasons; Shoulder Injuries; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Sirtuins; Skull Fractures; Social Determinants of Health; Sodium; Sodium Fluoride; Sodium Potassium Chloride Symporter Inhibitors; Sodium-Glucose Transporter 2 Inhibitors; Soil; Soil Pollutants; Spain; Spectrophotometry; Spectroscopy, Fourier Transform Infrared; Staphylococcal Protein A; Staphylococcus aureus; Stem Cells; Stereoisomerism; Stomach Neoplasms; Streptomyces; Strontium; Structure-Activity Relationship; Students, Nursing; Substance-Related Disorders; Succinic Acid; Sulfur; Surface Properties; Survival Rate; Survivin; Symporters; T-Lymphocytes; Temozolomide; Tensile Strength; Thiazoles; Thiobacillus; Thiohydantoins; Thiourea; Thrombectomy; Time Factors; Titanium; Tobacco Mosaic Virus; Tobacco Use Disorder; Toll-Like Receptor 4; Toluene; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Toxicity Tests, Acute; Toxicity Tests, Subacute; Transcriptional Activation; Treatment Outcome; Troponin I; Tumor Cells, Cultured; Tumor Escape; Tumor Hypoxia; Tumor Microenvironment; Tumor Necrosis Factor Inhibitors; Tumor Necrosis Factor-alpha; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination; Ultrasonic Waves; United Kingdom; United States; United States Department of Veterans Affairs; Up-Regulation; Urea; Uric Acid; Urinary Bladder Neoplasms; Urinary Bladder, Neurogenic; Urine; Urodynamics; User-Computer Interface; Vemurafenib; Verbenaceae; Veterans; Veterans Health; Viral Load; Virtual Reality; Vitiligo; Water Pollutants, Chemical; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Xylenes; Young Adult; Zinc; Zinc Oxide; Zinc Sulfate; Zoonoses	2021
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria. Expert opinion on pharmacotherapy, 2013, Volume: 14, Issue:18 Topics: Adult; Aged; Albumins; Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Bradykinin; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Imidazolidines; Male; Middle Aged; Natriuretic Peptide, Brain; Prospective Studies; Ramipril; Treatment Outcome	2013
Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes, obesity & metabolism, 2016, Volume: 18, Issue:6 Topics: Adult; Angiotensin II; Atrial Natriuretic Factor; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Heart Rate; Humans; Kidney; Kidney Function Tests; Liraglutide; Male; Middle Aged; Placebos; Renal Circulation; Renin-Angiotensin System	2016
Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes, 2017, Volume: 66, Issue:1 Topics: Aged; Angiotensin II; Body Weight; C-Reactive Protein; Caloric Restriction; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Obesity, Abdominal; Risk Factors	2017
Effects of cardiovascular angiotensin II type 1 receptor blockade on nitric oxide synthase inhibition in patients with insulin resistance syndrome. Blood pressure, 2009, Volume: 18, Issue:3 Topics: Adult; Angiotensin II; Arteries; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular System; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Hemodynamics; Humans; Insulin Resistance; Male; Metabolic Syndrome; Nitric Oxide Synthase; omega-N-Methylarginine; Photoplethysmography; Receptor, Angiotensin, Type 1; Telmisartan; Vascular Resistance	2009
Pioglitazone decreases plasma angiotensin II concentration in type 2 diabetes. Journal of atherosclerosis and thrombosis, 2010, Jun-30, Volume: 17, Issue:6 Topics: Adipocytes; Aged; Angiotensin II; Biomarkers; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin; Lipoprotein Lipase; Male; Middle Aged; Pioglitazone; ras Proteins; Thiazolidinediones	2010
Effects of hormone replacement therapy on cardiovascular responses in postmenopausal women with and without type 2 diabetes. Maturitas, 2002, Nov-20, Volume: 43, Issue:3 Topics: Administration, Oral; Angiotensin II; Blood Pressure; Cardiovascular System; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone; Middle Aged; Norepinephrine; Postmenopause; Stress, Physiological; Treatment Outcome	2002
Vasoconstricting effect of angiotensin II in human hand veins: influence of aging, diabetes mellitus and hypertension. Hypertension research : official journal of the Japanese Society of Hypertension, 2002, Volume: 25, Issue:5 Topics: Adult; Aged; Aging; Angiotensin II; Diabetes Mellitus, Type 2; Hand; Humans; Hypertension; Male; Middle Aged; Tachyphylaxis; Vasoconstriction; Vasoconstrictor Agents; Veins	2002
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. The New England journal of medicine, 2003, Jan-30, Volume: 348, Issue:5 Topics: Amputation, Surgical; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Exercise; Female; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Smoking Cessation; Stroke; Vitamins	2003
Losartan in diabetic nephropathy. Drugs, 2003, Volume: 63, Issue:4 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Relationship, Drug; Humans; Kidney Failure, Chronic; Losartan; Receptor, Angiotensin, Type 1	2003
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Annals of internal medicine, 2003, Apr-01, Volume: 138, Issue:7 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Creatinine; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Risk Factors; Tetrazoles; Treatment Outcome	2003
[The Steno-2 study. Intensive multifactorial intervention reduces the occurrence of cardiovascular disease in patients with type 2 diabetes]. Ugeskrift for laeger, 2003, Jun-23, Volume: 165, Issue:26 Topics: Amputation, Surgical; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Fat-Restricted; Exercise; Female; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Obesity; Risk Factors; Smoking Cessation; Stroke; Vitamins	2003
Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes care, 2003, Volume: 26, Issue:12 Topics: Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Blood Pressure; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Humans; Irbesartan; Kidney Function Tests; Male; Middle Aged; Placebos; Tetrazoles	2003
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme. Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:5 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Germany; Heart Diseases; Humans; Hypertension; Prognosis; Ramipril; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Risk Reduction Behavior; Telmisartan; Treatment Outcome	2004
Effects of angiotensin type-1 receptor antagonism on small artery function in patients with type 2 diabetes mellitus. Hypertension (Dallas, Tex. : 1979), 2005, Volume: 45, Issue:2 Topics: Acetylcholine; Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Arteries; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Humans; Male; Middle Aged; Nitroprusside; Tetrazoles; Vasoconstriction; Vasoconstrictor Agents; Vasodilation; Vasodilator Agents	2005
Effects of cerivastatin on forearm vascular responses, blood pressure responsiveness and ambulatory blood pressure in type 2 diabetic men. Diabetes, obesity & metabolism, 2005, Volume: 7, Issue:3 Topics: Acetylcholine; Aged; Analysis of Variance; Angiotensin II; Blood Pressure Monitoring, Ambulatory; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Endothelium, Vascular; Forearm; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Infusions, Intravenous; Male; Middle Aged; Nitric Oxide Synthase; Nitroprusside; Norepinephrine; omega-N-Methylarginine; Pyridines; Vascular Resistance; Vasodilator Agents	2005
Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study. Diabetologia, 2005, Volume: 48, Issue:10 Topics: Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Humans; Hypertrophy, Left Ventricular; Losartan; Male; Middle Aged; Risk Assessment; Treatment Outcome	2005
Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clinical nephrology, 2005, Volume: 64, Issue:3 Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Biphenyl Compounds; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Hypertension; Irbesartan; Male; Middle Aged; Perindopril; Renin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome	2005
Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. Diabetes research and clinical practice, 2006, Volume: 72, Issue:2 Topics: Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Genotype; Humans; Male; Peptidyl-Dipeptidase A; Polymorphism, Genetic; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Transforming Growth Factor beta	2006
Dual blockade of angiotensin II with enalapril and losartan reduces proteinuria in hypertensive patients with type 2 diabetes. Endocrine journal, 2006, Volume: 53, Issue:4 Topics: Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; C-Reactive Protein; Cystatin C; Cystatins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enalapril; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Proteinuria; Transforming Growth Factor beta	2006
Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. Hypertension (Dallas, Tex. : 1979), 2007, Volume: 49, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Arteries; Atenolol; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Receptor, Angiotensin, Type 2; Tetrazoles; Valine; Valsartan; Vascular Resistance; Vasodilation	2007
Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Journal of the American Society of Nephrology : JASN, 2007, Volume: 18, Issue:5 Topics: Aged; Albuminuria; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Humans; Hypertension; Losartan; Male; Middle Aged; Placebos	2007
Gradual reactivation of vascular angiotensin I to angiotensin II conversion during chronic ACE inhibitor therapy in patients with diabetes mellitus. Diabetologia, 2007, Volume: 50, Issue:10 Topics: Adult; Aged; Aldosterone; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Flow Velocity; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Hypertension; Kinetics; Lisinopril; Male; Middle Aged	2007
Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. Diabetologia, 2008, Volume: 51, Issue:5 Topics: Aged; Aldosterone; Angiotensin II; Blood Glucose; Blood Pressure; Body Mass Index; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Endothelium, Vascular; Female; Fibroblast Growth Factors; Glycated Hemoglobin; Humans; Hydrocortisone; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain	2008
Pressor and subpressor doses of angiotensin II increase insulin sensitivity in NIDDM. Dissociation of metabolic and blood pressure effects. Diabetes, 1994, Volume: 43, Issue:12 Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; C-Peptide; Cardiac Output; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Heart Rate; Humans; Insulin; Male; Middle Aged; Placebos; Potassium; Triglycerides	1994
Treatment of non-insulin-dependent diabetic hypertensive patients with Ca2+ channel blockers is associated with increased platelet sensitivity to insulin. American journal of hypertension, 1995, Volume: 8, Issue:12 Pt 1 Topics: Angiotensin II; Antihypertensive Agents; Blood Platelets; Blood Pressure; Calcium; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diltiazem; Double-Blind Method; Female; Humans; Hypertension; Hypoglycemic Agents; Insulin; Insulin Resistance; Isradipine; Male; Middle Aged; Vasoconstrictor Agents	1995
Comparative effects of glibenclamide and metformin on ambulatory blood pressure and cardiovascular reactivity in NIDDM. Diabetes care, 1997, Volume: 20, Issue:5 Topics: Acetylcholine; Adult; Aged; Angiotensin II; Blood Glucose; Blood Pressure; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Diazoxide; Double-Blind Method; Female; Forearm; Glyburide; Heart Rate; Hemodynamics; Humans; Hypoglycemic Agents; Infusions, Intra-Arterial; Lipoproteins; Male; Metformin; Middle Aged; Nitroprusside; Norepinephrine; Regional Blood Flow; Vascular Resistance	1997
Altered action of angiotensin II in patients with type 2 diabetes mellitus of recent onset. Journal of hypertension, 1997, Volume: 15, Issue:3 Topics: Adult; Angiotensin II; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Clamp Technique; Humans; Insulin; Male; Middle Aged; Muscle, Skeletal; Reference Values; Regional Blood Flow; Renal Circulation; Sodium	1997
Dietary sodium restriction impairs insulin sensitivity in noninsulin-dependent diabetes mellitus. The Journal of clinical endocrinology and metabolism, 1998, Volume: 83, Issue:5 Topics: Aged; Aldosterone; Angiotensin II; Cross-Over Studies; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Double-Blind Method; Electrolytes; Female; Glucose; Glucose Clamp Technique; Humans; Insulin; Male; Middle Aged; Placebos; Renin; Triglycerides	1998
Effects of glibenclamide on blood pressure and cardiovascular responsiveness in non-insulin dependent diabetes mellitus. Journal of hypertension, 1998, Volume: 16, Issue:5 Topics: Acetylcholine; Adult; Aged; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Forearm; Glyburide; Humans; Hypoglycemic Agents; Male; Middle Aged; Nitroprusside; Norepinephrine; Regional Blood Flow; Vasoconstriction; Vasoconstrictor Agents	1998
The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus. American journal of hypertension, 1999, Volume: 12, Issue:4 Pt 1 Topics: Adult; Aged; Aldosterone; Angiotensin II; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Female; Humans; Hypertension; Male; Middle Aged; Posture; Renin; Renin-Angiotensin System; Vasoconstrictor Agents; Zona Glomerulosa	1999
Relationship between polymorphism in the angiotensinogen, angiotensin-converting enzyme or angiotensin II receptor and renal progression in Japanese NIDDM patients. Nephron, 1999, Volume: 82, Issue:2 Topics: Aged; Angiotensin II; Angiotensinogen; Diabetes Mellitus, Type 2; Disease Progression; DNA; Female; Genotype; Humans; Japan; Male; Middle Aged; Peptidyl-Dipeptidase A; Polymerase Chain Reaction; Polymorphism, Genetic; Receptors, Angiotensin	1999
[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]. Ugeskrift for laeger, 2001, Oct-01, Volume: 163, Issue:40 Topics: Adult; Aged; Angiotensin II; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Humans; Losartan; Male; Middle Aged; Renin-Angiotensin System	2001
[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]. Ugeskrift for laeger, 2001, Oct-01, Volume: 163, Issue:40 Topics: Adult; Aged; Albuminuria; Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Irbesartan; Male; Middle Aged; Renin-Angiotensin System; Tetrazoles	2001
A low-sodium diet potentiates the effects of losartan in type 2 diabetes. Diabetes care, 2002, Volume: 25, Issue:4 Topics: Albuminuria; Aldosterone; Angiotensin II; Antihypertensive Agents; Blood Glucose; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Drug Synergism; Female; Hemodynamics; Humans; Losartan; Male; Middle Aged; Placebos; Renal Circulation; Renin; Sodium	2002
Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned? Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000, Volume: 1, Issue:4 Topics: Adult; Aged; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Captopril; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Enalapril; Humans; Middle Aged; Peptidyl-Dipeptidase A; Renin; Time Factors	2000

Other Studies

120 other study(ies) available for angiotensin ii and Diabetes Mellitus, Type 2

Article	Year
Protective effects of combining SERMs with estrogen on metabolic parameters in postmenopausal diabetic cardiovascular dysfunction: The role of cytokines and angiotensin II. Steroids, 2022, Volume: 183 Topics: Angiotensin II; Animals; Cytokines; Diabetes Mellitus, Type 2; Estrogens; Female; Interleukin-10; Postmenopause; Raloxifene Hydrochloride; Rats; Selective Estrogen Receptor Modulators; Tamoxifen; Tumor Necrosis Factor-alpha	2022
Changes of ACE2 in different glucose metabolites and its relationship with COVID-19. Medicine, 2022, Oct-14, Volume: 101, Issue:41 Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; C-Reactive Protein; COVID-19; Diabetes Mellitus, Type 2; Glucose; Humans; Interleukin-6; Peptide Fragments; Prediabetic State	2022
Vitamin D deficiency enhances vascular oxidative stress, inflammation, and angiotensin II levels in the microcirculation of diabetic patients. Microvascular research, 2023, Volume: 150 Topics: Angiotensin II; Diabetes Mellitus, Type 2; Humans; Inflammation; Microcirculation; Oxidative Stress; Superoxide Dismutase; Tumor Necrosis Factor-alpha; Vitamin D Deficiency	2023
Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme. European journal of pharmacology, 2019, Nov-05, Volume: 862 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enalapril; Female; Glucagon-Like Peptide 1; Humans; Hypertension; Linagliptin; Peptidyl-Dipeptidase A; Protein Binding; Rats; Rats, Sprague-Dawley; Sitagliptin Phosphate	2019
Rho kinase cascade activation in circulating leukocytes in patients with diabetes mellitus type 2. Cardiovascular diabetology, 2020, 05-06, Volume: 19, Issue:1 Topics: Aged; Angiotensin II; Antihypertensive Agents; Biomarkers; Case-Control Studies; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Enzyme Activation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Intercellular Adhesion Molecule-1; Interleukin-8; Janus Kinase 2; Leukocytes, Mononuclear; Male; Malondialdehyde; Middle Aged; p38 Mitogen-Activated Protein Kinases; rho-Associated Kinases; Signal Transduction; Vascular Cell Adhesion Molecule-1	2020
Angiotensin Type 1 Receptor-Dependent Internalization of SARS-CoV-2 by Angiotensin-Converting Enzyme 2. Hypertension (Dallas, Tex. : 1979), 2021, Volume: 77, Issue:4 Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; COVID-19; Diabetes Mellitus, Type 2; Humans; Peptidyl-Dipeptidase A; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; SARS-CoV-2	2021
Angiotensin II promotes the anticoagulant effects of rivaroxaban via angiotensin type 2 receptor signaling in mice. Scientific reports, 2017, 03-23, Volume: 7, Issue:1 Topics: Angiotensin II; Animals; Cells, Cultured; Cytokines; Diabetes Mellitus, Type 2; Disease Models, Animal; Factor Xa Inhibitors; Glycation End Products, Advanced; Human Umbilical Vein Endothelial Cells; Humans; Inflammation Mediators; Mice, Inbred C57BL; Proto-Oncogene Mas; Proto-Oncogene Proteins; Receptor, Angiotensin, Type 2; Receptors, G-Protein-Coupled; Rivaroxaban; Signal Transduction	2017
[Irbesartan ameliorates cardiac inflammation in type 2 diabetic db/db mice]. Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2016, Apr-20, Volume: 37, Issue:4 Topics: Actins; Angiotensin II; Animals; Biphenyl Compounds; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Inflammation; Interleukin-6; Irbesartan; Mice; Obesity; Random Allocation; Real-Time Polymerase Chain Reaction; Signal Transduction; Tetrazoles; Transcription Factor RelA; Tumor Necrosis Factor-alpha	2016
Association of angiotensin-II levels with albuminuria in subjects with normal glucose metabolism, prediabetes, and type 2 diabetes mellitus. Journal of diabetes and its complications, 2017, Volume: 31, Issue:10 Topics: Aged; Albuminuria; Angiotensin II; Biomarkers; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Early Diagnosis; Endothelium, Vascular; Female; Hospitals, University; Humans; Insulin Resistance; Male; Microvessels; Middle Aged; Outpatient Clinics, Hospital; Prediabetic State; Republic of Korea; Risk Factors; Up-Regulation; Vasculitis	2017
Angiotensin II Causes β-Cell Dysfunction Through an ER Stress-Induced Proinflammatory Response. Endocrinology, 2017, 10-01, Volume: 158, Issue:10 Topics: Angiotensin II; Animals; Cell Line, Tumor; Cytokines; Diabetes Mellitus, Type 2; eIF-2 Kinase; Endoplasmic Reticulum Stress; Endoribonucleases; Gene Expression; Gene Knockdown Techniques; Glucose; Inflammation; Inositol 1,4,5-Trisphosphate Receptors; Insulin-Secreting Cells; Insulinoma; Islets of Langerhans; Male; Mice; Mice, Inbred C57BL; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Reactive Oxygen Species; Renin-Angiotensin System; RNA, Small Interfering; Taurine; Ursodeoxycholic Acid	2017
Esculetin ameliorates vascular perturbation by intervening in the occupancy of H2BK120Ub at At1, At2, Tgfβ1 and Mcp1 promoter gene in thoracic aorta of IR and T2D rats. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2017, Volume: 95 Topics: Acetylcholine; Angiotensin II; Animals; Aorta; Blood Vessels; Chemokine CCL2; Diabetes Mellitus, Type 2; Gene Expression Regulation; Hemodynamics; Histones; Insulin Resistance; Lysine; Muscle Relaxation; Myocardial Contraction; Promoter Regions, Genetic; Rats; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; RNA, Messenger; Transforming Growth Factor beta1; Ubiquitin; Umbelliferones	2017
Regulation of diabetic cardiomyopathy by caloric restriction is mediated by intracellular signaling pathways involving 'SIRT1 and PGC-1α'. Cardiovascular diabetology, 2018, 08-02, Volume: 17, Issue:1 Topics: Angiotensin II; Animals; Caloric Restriction; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Fibrosis; Hypertension; Male; Mice, Inbred C57BL; Myocardium; Obesity; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rats, Sprague-Dawley; Signal Transduction; Sirtuin 1; Ventricular Remodeling	2018
Reversal of angiotensin ll-induced β-cell dedifferentiation via inhibition of NF-κb signaling. Molecular medicine (Cambridge, Mass.), 2018, 08-14, Volume: 24, Issue:1 Topics: Angiotensin II; Animals; Cell Dedifferentiation; Cell Line, Tumor; Diabetes Mellitus, Type 2; Gene Expression; Insulin; Insulin-Secreting Cells; Male; Mice, Inbred C57BL; NF-kappa B; Rats; Renin-Angiotensin System; Signal Transduction	2018
Participation of the AngII/TRPC6/NFAT axis in the pathogenesis of podocyte injury in rats with type 2 diabetes. Molecular medicine reports, 2019, Volume: 19, Issue:3 Topics: Albuminuria; Angiotensin II; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Glucose; Humans; Kidney Glomerulus; NFATC Transcription Factors; Podocytes; Rats; TRPC6 Cation Channel	2019
The Role of Heme Oxygenase 1 in the Protective Effect of Caloric Restriction against Diabetic Cardiomyopathy. International journal of molecular sciences, 2019, May-16, Volume: 20, Issue:10 Topics: Angiotensin II; Animals; Blood Glucose; Caloric Restriction; Carbazoles; Cardiomegaly; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Heme Oxygenase-1; Male; Malondialdehyde; Mesoporphyrins; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Obesity; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Protoporphyrins; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Signal Transduction; Sirtuin 1	2019
Pancreatic angiotensin-converting enzyme 2 improves glycemia in angiotensin II-infused mice. American journal of physiology. Endocrinology and metabolism, 2013, Apr-15, Volume: 304, Issue:8 Topics: Adaptor Proteins, Signal Transducing; Adenoviridae; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; C-Peptide; Diabetes Mellitus, Type 2; Genetic Therapy; Humans; Hyperglycemia; Insulin; Insulin Resistance; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Peptidyl-Dipeptidase A; Renin-Angiotensin System; Vasoconstrictor Agents	2013
Ang(1-7) treatment attenuates β-cell dysfunction by improving pancreatic microcirculation in a rat model of Type 2 diabetes. Journal of endocrinological investigation, 2013, Volume: 36, Issue:11 Topics: Angiotensin I; Angiotensin II; Animals; Apoptosis; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Insulin; Insulin Secretion; Islets of Langerhans; Male; Microcirculation; Nitric Oxide; Nitric Oxide Synthase Type III; Pancreas; Peptide Fragments; Rats; Rats, Wistar	2013
Angiotensin II contributes to diabetic renal dysfunction in rodents and humans via Notch1/Snail pathway. The American journal of pathology, 2013, Volume: 183, Issue:1 Topics: Aged; Angiotensin II; Animals; Case-Control Studies; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Down-Regulation; Female; Humans; Immunohistochemistry; Kidney; Linear Models; Male; Membrane Proteins; Microscopy, Electron, Transmission; Middle Aged; Rats; Rats, Sprague-Dawley; Rats, Zucker; Real-Time Polymerase Chain Reaction; Receptor, Notch1; Snail Family Transcription Factors; Transcription Factors	2013
[Effects of shenqi compound on the mRNA expression of AT1R in the aorta of GK rats]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2013, Volume: 33, Issue:3 Topics: Angiotensin II; Animals; Aorta; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Male; Rats; Receptor, Angiotensin, Type 1; RNA, Messenger; Triglycerides	2013
An ethanolic extract of Lindera obtusiloba stems, YJP-14, improves endothelial dysfunction, metabolic parameters and physical performance in diabetic db/db mice. PloS one, 2013, Volume: 8, Issue:6 Topics: Albuminuria; Angiotensin II; Animals; Aorta; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelium, Vascular; Ethanol; Exercise Tolerance; Gene Expression; Humans; Hyperglycemia; Hypoglycemic Agents; Lindera; Male; Mice; Mice, Transgenic; NADPH Oxidases; Nitric Oxide Synthase Type III; Pioglitazone; Plant Extracts; Prostaglandin-Endoperoxide Synthases; Receptor, Angiotensin, Type 1; Thiazolidinediones	2013
Regulation of urinary ACE2 in diabetic mice. American journal of physiology. Renal physiology, 2013, Aug-15, Volume: 305, Issue:4 Topics: Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Biomarkers; Blotting, Western; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Male; Mice; Mice, Inbred C57BL; Peptidyl-Dipeptidase A	2013
Beneficial effects of β-conglycinin on renal function and nephrin expression in early streptozotocin-induced diabetic nephropathy rats. The British journal of nutrition, 2014, Jan-14, Volume: 111, Issue:1 Topics: Angiotensin II; Animals; Antigens, Plant; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dietary Proteins; Globulins; Glycation End Products, Advanced; Glycine max; Insulin Resistance; Isoflavones; Kidney; Male; Membrane Proteins; Peptidyl-Dipeptidase A; Phytotherapy; Plant Preparations; Rats; Rats, Inbred SHR; Seed Storage Proteins; Soybean Proteins; Thiobarbituric Acid Reactive Substances; Triglycerides	2014
Boldine improves endothelial function in diabetic db/db mice through inhibition of angiotensin II-mediated BMP4-oxidative stress cascade. British journal of pharmacology, 2013, Volume: 170, Issue:6 Topics: Angiotensin II; Animals; Antioxidants; Aorta, Thoracic; Aporphines; Bone Morphogenetic Protein 4; Cells, Cultured; Diabetes Mellitus, Type 2; Endothelial Cells; Endothelium, Vascular; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Nitric Oxide Synthase Type III; Oxidative Stress; Receptor, Angiotensin, Type 1; Vasodilation	2013
Advanced glycation end products and diabetic nephropathy: a comparative study using diabetic and normal rats with methylglyoxal-induced glycation. Journal of physiology and biochemistry, 2014, Volume: 70, Issue:1 Topics: Angiotensin II; Animals; Apoptosis; Apoptosis Regulatory Proteins; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Glycation End Products, Advanced; Kidney; Organ Size; Pyruvaldehyde; Rats; Rats, Wistar; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Vascular Endothelial Growth Factor A; Weight Gain	2014
Hypertension is a conditional factor for the development of cardiac hypertrophy in type 2 diabetic mice. PloS one, 2014, Volume: 9, Issue:1 Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Blood Pressure; Cell Size; Diabetes Mellitus, Type 2; Dobutamine; Gene Expression; Glycation End Products, Advanced; Hypertension; Hypertrophy, Left Ventricular; Male; Mice; Myocardium; Myocytes, Cardiac; Time Factors; Ultrasonography; Ventricular Function, Left; Ventricular Remodeling	2014
Relationships among protein tyrosine phosphatase 1B, angiotensin II, and insulin-mediated aortic responses in type 2 diabetic Goto-Kakizaki rats. Atherosclerosis, 2014, Volume: 233, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Insulin; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Receptor, Angiotensin, Type 1; Vasodilation	2014
Angiotensin II induces interleukin-1β-mediated islet inflammation and β-cell dysfunction independently of vasoconstrictive effects. Diabetes, 2015, Volume: 64, Issue:4 Topics: Angiotensin II; Animals; Apoptosis; Blood Glucose; Chemokine CCL2; Diabetes Mellitus, Type 2; Diet, High-Fat; Humans; Inflammation; Insulin; Insulin Secretion; Interleukin-1beta; Islets of Langerhans; Mice; Mitochondria; Renin-Angiotensin System; Vasoconstriction	2015
Overactive cannabinoid 1 receptor in podocytes drives type 2 diabetic nephropathy. Proceedings of the National Academy of Sciences of the United States of America, 2014, Dec-16, Volume: 111, Issue:50 Topics: Analysis of Variance; Angiotensin II; Animals; Arachidonic Acids; Desmin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Gene Expression Regulation; Losartan; Models, Biological; Podocytes; Pyrazoles; Rats; Rats, Zucker; Receptor, Angiotensin, Type 1; Receptor, Cannabinoid, CB1; RNA Interference; RNA, Small Interfering; Sulfonamides	2014
Bone Morphogenic Protein 4 Mediates NOX1-Dependent eNOS Uncoupling, Endothelial Dysfunction, and COX2 Induction in Type 2 Diabetes Mellitus. Molecular endocrinology (Baltimore, Md.), 2015, Volume: 29, Issue:8 Topics: Angiotensin II; Animals; Aorta; Biopterins; Blood Glucose; Bone Morphogenetic Protein 4; Carrier Proteins; Cattle; Cells, Cultured; Cholesterol; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Endothelial Cells; Endothelium, Vascular; Inflammation; Male; Mice; NADH, NADPH Oxidoreductases; NADPH Oxidase 1; Nitric Oxide Synthase Type III; RNA, Small Interfering; Superoxides	2015
The angiotensin receptor blocker losartan reduces coronary arteriole remodeling in type 2 diabetic mice. Vascular pharmacology, 2016, Volume: 76 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arterioles; Blood Pressure; Coronary Vessels; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hypertension; Losartan; Male; Mice; Microvessels; Muscle, Smooth, Vascular; Pilot Projects; Receptor, Angiotensin, Type 1; Renin-Angiotensin System	2016
Circulating adiponectin concentrations are increased by dietary resistant starch and correlate with serum 25-hydroxycholecalciferol concentrations and kidney function in Zucker diabetic fatty rats. Nutrition research (New York, N.Y.), 2016, Volume: 36, Issue:4 Topics: Adiponectin; Adiposity; Angiotensin II; Animals; Blood Glucose; Calcifediol; Diabetes Mellitus, Type 2; Dietary Carbohydrates; Gene Expression; Glycated Hemoglobin; Insulin; Kidney; Male; Membrane Proteins; Rats; Rats, Zucker; Renin-Angiotensin System; Signal Transduction; Starch	2016
Effect of angiotensin II type 1 receptor blocker on 12-lipoxygenase activity and slit diaphragm protein expression in type 2 diabetic rat glomeruli. Journal of nephrology, 2016, Volume: 29, Issue:6 Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Arachidonate 12-Lipoxygenase; Cadherins; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diet, High-Fat; Kidney Glomerulus; Lipoxygenase Inhibitors; Losartan; Male; Membrane Proteins; Mice; Podocytes; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Streptozocin	2016
Cathepsin A mediates susceptibility to atrial tachyarrhythmia and impairment of atrial emptying function in Zucker diabetic fatty rats. Cardiovascular research, 2016, 06-01, Volume: 110, Issue:3 Topics: Action Potentials; Angiotensin II; Animals; Atrial Fibrillation; Atrial Function, Left; Atrial Remodeling; Bradykinin; Cathepsin A; Connexin 43; Diabetes Mellitus, Type 2; Disease Models, Animal; Fibrosis; Heart Rate; Mice, Inbred C57BL; Mice, Transgenic; Myocardium; Protease Inhibitors; Rats, Zucker; Time Factors	2016
Long-Term Supplementation of Microencapsulated ursodeoxycholic Acid Prevents Hypertension in a Mouse Model of Insulin Resistance. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2017, Volume: 125, Issue:1 Topics: Angiotensin II; Animals; Capsules; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dietary Supplements; Disease Models, Animal; Hypertension; Insulin Resistance; Male; Mice; Time Factors; Ursodeoxycholic Acid	2017
Angiotensin II Promotes the Development of Carotid Atherosclerosis in Type 2 Diabetes Patients via Regulating the T Cells Activities: A Cohort Study. Medical science monitor : international medical journal of experimental and clinical research, 2016, Oct-26, Volume: 22 Topics: Adult; Aged; Angiotensin II; Carotid Artery Diseases; Cohort Studies; Cytokines; Diabetes Mellitus, Type 2; Female; Humans; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Middle Aged; Phenotype; T-Lymphocyte Subsets; T-Lymphocytes	2016
Glucose and angiotensin II-derived endothelial extracellular vesicles regulate endothelial dysfunction via ERK1/2 activation. Pflugers Archiv : European journal of physiology, 2017, Volume: 469, Issue:2 Topics: Angiotensin II; Animals; Aorta; Diabetes Mellitus, Type 2; Endothelium, Vascular; Extracellular Vesicles; Glucose; Human Umbilical Vein Endothelial Cells; Humans; Male; MAP Kinase Signaling System; Mice; Mice, Inbred ICR; Nitric Oxide; Nitric Oxide Synthase Type III; Signal Transduction	2017
Chronic blockade of the AT2 receptor with PD123319 impairs insulin signaling in C57BL/6 mice. Peptides, 2017, Volume: 88 Topics: Adiponectin; Adipose Tissue; Angiotensin II; Angiotensin II Type 2 Receptor Blockers; Animals; Chemokine CCL2; Diabetes Mellitus, Type 2; Humans; Hypertension; Imidazoles; Insulin; Insulin Resistance; Interleukin-6; Losartan; Mice; Mice, Knockout; Pyridines; Receptor, Angiotensin, Type 2; Signal Transduction; Tumor Necrosis Factor-alpha	2017
Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. Journal of hypertension, 2008, Volume: 26, Issue:9 Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Blood Glucose; Blood Pressure; Collagen; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Hypertension, Renal; Kidney Cortex; Male; Podocytes; Rats; Rats, Inbred OLETF; RNA, Messenger; Telmisartan	2008
Intact renal afferent arteriolar autoregulatory responsiveness in db/db mice. American journal of physiology. Renal physiology, 2008, Volume: 295, Issue:5 Topics: Albuminuria; Angiotensin II; Animals; Arterioles; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucose; Heart Rate; Homeostasis; Male; Mannitol; Mice; Mice, Obese; Motor Activity; Receptors, Leptin; Renal Circulation; Renin-Angiotensin System; Telemetry	2008
Involvement of angiotensin II-dependent vascular endothelial growth factor gene expression via NADPH oxidase in the retina in a type 2 diabetic rat model. Current eye research, 2008, Volume: 33, Issue:10 Topics: Administration, Oral; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Gene Expression Regulation; NADPH Oxidases; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Retina; RNA, Messenger; Tetrazoles; Vascular Endothelial Growth Factor A	2008
Impaired insulin-mediated vasorelaxation in diabetic Goto-Kakizaki rats is caused by impaired Akt phosphorylation. American journal of physiology. Cell physiology, 2009, Volume: 296, Issue:2 Topics: Adenoviridae; Angiotensin II; Animals; Aorta; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Genetic Vectors; Humans; Insulin; Insulin Resistance; Male; Microtubule-Associated Proteins; Muscle, Smooth, Vascular; Myography; Nitric Oxide Synthase Type II; Phosphorylation; Protein Phosphatase 1; Proto-Oncogene Proteins c-akt; Rats; Rats, Inbred WKY; Recombinant Proteins; RNA Interference; Signal Transduction; Survivin; Transfection; Vasoconstriction; Vasodilation	2009
Ang-II-induced Ca(2+) influx is mediated by the 1/4/5 subgroup of the transient receptor potential proteins in cultured aortic smooth muscle cells from diabetic Goto-Kakizaki rats. Molecular and cellular endocrinology, 2009, Apr-10, Volume: 302, Issue:1 Topics: Angiotensin II; Animals; Aorta; Blotting, Western; Calcium; Calcium Signaling; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Rats; Rats, Inbred WKY; RNA, Messenger; Transient Receptor Potential Channels; TRPC Cation Channels	2009
Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. Journal of pharmacological sciences, 2009, Volume: 109, Issue:2 Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fibrosis; Heart Failure; Hyperglycemia; Male; Myocardium; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Tetrazoles	2009
Cardiovascular and autonomic phenotype of db/db diabetic mice. Experimental physiology, 2009, Volume: 94, Issue:6 Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Autonomic Nervous System; Baroreflex; Blood Pressure; Cardiovascular System; Circadian Rhythm; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Models, Animal; Heart Rate; Hypertension; Losartan; Male; Mice; Mice, Mutant Strains; Motor Activity; Peptidyl-Dipeptidase A; Phenotype; Receptor, Angiotensin, Type 1; Receptors, Leptin	2009
Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat. American journal of physiology. Heart and circulatory physiology, 2009, Volume: 296, Issue:5 Topics: Angiotensin II; Animals; Arginine Vasopressin; Butadienes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelin-1; Endothelins; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Male; MAP Kinase Kinase Kinases; Mesenteric Arteries; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitriles; Nitroarginine; Nitroprusside; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Signal Transduction; Vasoconstriction; Vasodilation	2009
Circulating angiotensin II is associated with body fat accumulation and insulin resistance in obese subjects with type 2 diabetes mellitus. Metabolism: clinical and experimental, 2009, Volume: 58, Issue:5 Topics: Adiponectin; Adipose Tissue; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Humans; Insulin Resistance; Leptin; Lipoprotein Lipase; Male; Middle Aged; Obesity; Tomography, X-Ray Computed; Weight Loss	2009
[Influence of chronic cardiac failure severity on the course of comorbid type 2 diabetes mellitus]. Terapevticheskii arkhiv, 2009, Volume: 81, Issue:9 Topics: Aged; Angiotensin II; C-Peptide; Comorbidity; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Insulin; Male; Middle Aged; Natriuretic Peptide, Brain; Norepinephrine; Retrospective Studies; Severity of Illness Index	2009
Major role for ACE-independent intrarenal ANG II formation in type II diabetes. American journal of physiology. Renal physiology, 2010, Volume: 298, Issue:1 Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Angiotensinogen; Animals; Arterioles; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Kidney; Male; Mice; Mice, Mutant Strains; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Receptors, Leptin; Serine Proteases; Signal Transduction; Vasoconstriction	2010
Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension (Dallas, Tex. : 1979), 2010, Volume: 55, Issue:2 Topics: Angiotensin II; Animals; Atherosclerosis; Cells, Cultured; Cohort Studies; Diabetes Mellitus, Type 2; Disease Models, Animal; Female; Humans; Hypertension; Interleukin-17; Lymphocyte Activation; Male; Mice; Mice, Inbred C57BL; Probability; Random Allocation; Reference Values; T-Lymphocytes; Vascular Diseases	2010
Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxidants & redox signaling, 2010, Sep-15, Volume: 13, Issue:6 Topics: Aged, 80 and over; Angiotensin II; Animals; Diabetes Mellitus, Type 2; Endothelial Cells; Glucose; Humans; Male; Mice; Mice, Inbred C57BL; Middle Aged; Oxidative Stress; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System	2010
Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clinical and experimental pharmacology & physiology, 2010, Volume: 37, Issue:7 Topics: Angiotensin II; Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemoglobin; Hypertension; Kidney; Male; Metabolic Syndrome; Proteinuria; Pyrazines; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Renal Circulation; Sitagliptin Phosphate; Triazoles; Vasoconstriction; Vasoconstrictor Agents	2010
Plasma concentration of visfatin is a new surrogate marker of systemic inflammation in type 2 diabetic patients. Diabetes research and clinical practice, 2010, Volume: 89, Issue:2 Topics: 3T3-L1 Cells; Adult; Aged; Angiotensin II; Animals; Biomarkers; Blotting, Western; Diabetes Mellitus, Type 2; Female; Gene Expression; Glucose; Humans; Inflammation; Male; Mice; Middle Aged; NF-kappa B; Nicotinamide Phosphoribosyltransferase; Polymerase Chain Reaction	2010
Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. Journal of hypertension, 2010, Volume: 28, Issue:11 Topics: Albuminuria; Angiotensin II; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Kidney; Kidney Glomerulus; Male; Podocytes; Rats; Rats, Long-Evans; Remission Induction; Sclerosis; Treatment Outcome	2010
Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation. European journal of clinical investigation, 2011, Volume: 41, Issue:6 Topics: Adult; Aged; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Female; Humans; Inflammation Mediators; Insulin Resistance; Interleukin-6; Male; Middle Aged; Regression Analysis; Tetrazoles; Time Factors; Treatment Outcome; Vasoconstrictor Agents	2011
Role of 12-lipoxygenase in decreasing P-cadherin and increasing angiotensin II type 1 receptor expression according to glomerular size in type 2 diabetic rats. American journal of physiology. Endocrinology and metabolism, 2011, Volume: 300, Issue:4 Topics: Angiotensin II; Animals; Arachidonate 12-Lipoxygenase; Cadherins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Down-Regulation; Gene Expression Regulation; Hydroxyeicosatetraenoic Acids; Kidney Glomerulus; Male; Organ Size; Proteinuria; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Streptozocin; Up-Regulation	2011
Attenuating effect of angiotensin-(1-7) on angiotensin II-mediated NAD(P)H oxidase activation in type 2 diabetic nephropathy of KK-A(y)/Ta mice. American journal of physiology. Renal physiology, 2011, Volume: 300, Issue:6 Topics: Angiotensin I; Angiotensin II; Animals; Blood Pressure; Blotting, Western; Body Weight; Cells, Cultured; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Immunohistochemistry; Mesangial Cells; Mice; NADPH Oxidases; Peptide Fragments; Reactive Oxygen Species; Reverse Transcriptase Polymerase Chain Reaction; Statistics, Nonparametric	2011
Angiotensin II causes endothelial dysfunction via the GRK2/Akt/eNOS pathway in aortas from a murine type 2 diabetic model. Pharmacological research, 2011, Volume: 64, Issue:5 Topics: Angiotensin II; Animals; Aorta; Diabetes Mellitus, Type 2; Endothelium, Vascular; G-Protein-Coupled Receptor Kinase 2; Male; Mice; Nitric Oxide; Nitric Oxide Synthase Type III; Proto-Oncogene Proteins c-akt	2011
Losartan improves aortic endothelium-dependent relaxation via proline-rich tyrosine kinase 2/Src/Akt pathway in type 2 diabetic Goto-Kakizaki rats. American journal of physiology. Heart and circulatory physiology, 2011, Volume: 301, Issue:6 Topics: 3-Phosphoinositide-Dependent Protein Kinases; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Blotting, Western; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Focal Adhesion Kinase 2; Immunohistochemistry; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Losartan; Nitric Oxide; Nitric Oxide Synthase Type III; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Signal Transduction; src-Family Kinases; Vasodilation; Vasodilator Agents	2011
Modified high-density lipoprotein modulates aldosterone release through scavenger receptors via extra cellular signal-regulated kinase and Janus kinase-dependent pathways. Molecular and cellular biochemistry, 2012, Volume: 366, Issue:1-2 Topics: Adrenal Glands; Aldosterone; Angiotensin II; Cell Line; Cell Proliferation; Cholesterol Esters; Diabetes Mellitus, Type 2; Gene Expression; Humans; Janus Kinase 2; Lipid Metabolism; Lipoproteins, HDL; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Oxidation-Reduction; Protein Kinase C; Scavenger Receptors, Class B; Thiobarbituric Acid Reactive Substances	2012
Heart angiotensin II-induced cardiomyocyte hypertrophy suppresses coronary angiogenesis and progresses diabetic cardiomyopathy. American journal of physiology. Heart and circulatory physiology, 2012, May-01, Volume: 302, Issue:9 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Apoptosis; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; Disease Models, Animal; Hypertrophy; Hypertrophy, Left Ventricular; Imidazoles; Male; Myocytes, Cardiac; Neovascularization, Physiologic; Olmesartan Medoxomil; Rats; Rats, Mutant Strains; Rats, Sprague-Dawley; Tetrazoles; Thrombospondin 1; Vascular Endothelial Growth Factor A; Ventricular Dysfunction, Left	2012
Angiotensin II type 2 receptor-dependent increase in nitric oxide synthase activity in the endothelium of db/db mice is mediated via a MEK pathway. Pharmacological research, 2012, Volume: 66, Issue:1 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Aorta; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelium, Vascular; Enzyme Activation; Flavonoids; Losartan; Male; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Nitric Oxide; Nitric Oxide Synthase Type III; Oligopeptides; Phosphorylation; Protein Kinase Inhibitors; Receptor, Angiotensin, Type 2; Signal Transduction; Time Factors; Vasodilation; Vasodilator Agents	2012
Add-on aliskiren elicits stronger renoprotection than high-dose valsartan in type 2 diabetic KKAy mice that do not respond to low-dose valsartan. Journal of pharmacological sciences, 2012, Volume: 119, Issue:2 Topics: Albuminuria; Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fumarates; Kidney; Male; Mice; Mice, Inbred C57BL; Renin; RNA, Messenger; Tetrazoles; Valine; Valsartan	2012
[Effects of two different extracts of total saponins from Cicer arietinum on kidney of T2DM rats]. Yao xue xue bao = Acta pharmaceutica Sinica, 2012, Volume: 47, Issue:4 Topics: 6-Ketoprostaglandin F1 alpha; Angiotensin II; Animals; Blood Glucose; Blood Urea Nitrogen; Cicer; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Endothelin-1; Glutathione Peroxidase; Hypoglycemic Agents; Insulin; Kidney; Male; Malondialdehyde; Plants, Medicinal; Random Allocation; Rats; Rats, Wistar; Saponins; Superoxide Dismutase; Thromboxane B2	2012
Direct evidence for intrarenal chymase-dependent angiotensin II formation on the diabetic renal microvasculature. Hypertension (Dallas, Tex. : 1979), 2013, Volume: 61, Issue:2 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Chymases; Diabetes Mellitus, Type 2; Kidney; Male; Mice; Microvessels; Peptidyl-Dipeptidase A; Tetrazoles	2013
Phosphorylation of myocardial eNOS is altered in patients suffering from type 2 diabetes. Journal of applied physiology (Bethesda, Md. : 1985), 2013, May-15, Volume: 114, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Angiotensin II; Diabetes Mellitus, Type 2; Dinoprost; Humans; Middle Aged; Myocardium; Nitric Oxide Synthase Type III; Oxidative Stress; Phosphorylation; Proto-Oncogene Proteins c-akt; Tyrosine	2013
Aberrant activation of the intrarenal renin-angiotensin system in the developing kidneys of type 2 diabetic rats. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2013, Volume: 45, Issue:5 Topics: Albuminuria; Angiotensin II; Angiotensinogen; Animals; Blood Glucose; Blood Pressure; Body Weight; Collagen; Connective Tissue Growth Factor; Creatinine; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Kidney; Organ Size; Peptidyl-Dipeptidase A; Rats; Rats, Inbred OLETF; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Time Factors; Transforming Growth Factor beta	2013
Role of ANG II in coronary capillary angiogenesis at the insulin-resistant stage of a NIDDM rat model. American journal of physiology. Heart and circulatory physiology, 2002, Volume: 283, Issue:4 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Capillaries; Coronary Circulation; Diabetes Mellitus, Type 2; Disease Models, Animal; Endothelial Growth Factors; Extracellular Matrix Proteins; Gene Expression; Glycation End Products, Advanced; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin Resistance; Lymphokines; Male; Neovascularization, Physiologic; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Receptor Protein-Tyrosine Kinases; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Messenger; Tetrazoles; Transcription Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2002
Diabetic nephropathy. The New England journal of medicine, 2002, Sep-19, Volume: 347, Issue:12 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Creatine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypertension	2002
Angiotensin blockade prevents type 2 diabetes by formation of fat cells. Hypertension (Dallas, Tex. : 1979), 2002, Volume: 40, Issue:5 Topics: Adipocytes; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Benzoates; Cell Differentiation; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Disease Models, Animal; Humans; Hypoglycemic Agents; Insulin Resistance; Obesity; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Telmisartan	2002
Gender difference in vascular and platelet reactivity to thromboxane A(2)-mimetic U46619 and to endothelial dependent vasodilation in Zucker fatty (hypertensive, hyperinsulinemic) diabetic rats. Diabetes research and clinical practice, 2003, Volume: 59, Issue:1 Topics: 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; Angiotensin II; Animals; Blood Pressure; Diabetes Mellitus, Type 2; Endothelin-1; Endothelium, Vascular; Enzyme Inhibitors; Female; Kidney Cortex; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phenylephrine; Platelet Aggregation; Rats; Rats, Zucker; Renal Circulation; Sex Characteristics; Vasoconstrictor Agents; Vasodilation	2003
Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes, 2003, Volume: 52, Issue:4 Topics: Adult; Aged; Albuminuria; Angiotensin II; Biopsy; Blotting, Western; Cells, Cultured; Cytochalasin B; Cytoskeleton; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Fluorescent Antibody Technique, Indirect; Gene Expression; Glycated Serum Albumin; Glycation End Products, Advanced; Humans; Kidney; Male; Membrane Proteins; Microscopy, Fluorescence; Middle Aged; Nephrotic Syndrome; Proteins; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serum Albumin; Tissue Distribution	2003
Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease. Annals of internal medicine, 2003, Apr-01, Volume: 138, Issue:7 Topics: Amlodipine; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Irbesartan; Kidney Failure, Chronic; Male; Middle Aged; Placebos; Risk Factors; Tetrazoles; Treatment Outcome	2003
[Microalbuminuria as a warning sign of diabetic nephropathy. Test your diabetics early!]. MMW Fortschritte der Medizin, 2003, Mar-06, Volume: 145, Issue:10 Topics: Adolescent; Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzothiadiazines; Calcium Channel Blockers; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diuretics; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Kidney Failure, Chronic; Risk Factors; Smoking Cessation; Sodium Chloride Symporter Inhibitors; Time Factors	2003
Role of angiotensin II in altered expression of molecules responsible for coronary matrix remodeling in insulin-resistant diabetic rats. Arteriosclerosis, thrombosis, and vascular biology, 2003, Nov-01, Volume: 23, Issue:11 Topics: Angiotensin II; Animals; Collagen Type I; Collagen Type III; Coronary Vessels; Diabetes Mellitus, Type 2; Down-Regulation; Fibrin; Fibrosis; Insulin Resistance; Matrix Metalloproteinase 2; Matrix Metalloproteinases; Rats; Rats, Inbred OLETF; Receptor, Melatonin, MT1; Transforming Growth Factor beta	2003
[Microalbuminuria is an early marker for increased morbidity and mortality]. Fortschritte der Medizin. Originalien, 2003, Feb-27, Volume: 121 Suppl 1 Topics: Albuminuria; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension; Losartan; Male; Meta-Analysis as Topic; Prevalence; Proteinuria; Renin-Angiotensin System; Risk Factors; Stroke	2003
Increased ACE 2 and decreased ACE protein in renal tubules from diabetic mice: a renoprotective combination? Hypertension (Dallas, Tex. : 1979), 2004, Volume: 43, Issue:5 Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Carboxypeptidases; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Enzyme Induction; Kidney Tubules; Lipids; Lung; Membrane Proteins; Mice; Myocardium; Organ Size; Organ Specificity; Peptidyl-Dipeptidase A; Renin-Angiotensin System; RNA, Messenger	2004
Comment: renal protective effects of angiotensin receptor blockers. The Annals of pharmacotherapy, 2004, Volume: 38, Issue:12 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Kidney Diseases	2004
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. Journal of the American Society of Nephrology : JASN, 2005, Volume: 16, Issue:3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Hydralazine; Imidazoles; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Male; NADPH Oxidases; Olmesartan Medoxomil; Prediabetic State; Rats; Rats, Inbred OLETF; Receptors, Angiotensin; Renin; Tetrazoles; Thiazepines; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta	2005
Increased expression of NAD(P)H oxidase in islets of animal models of Type 2 diabetes and its improvement by an AT1 receptor antagonist. Biochemical and biophysical research communications, 2005, Jul-15, Volume: 332, Issue:4 Topics: 8-Hydroxy-2'-Deoxyguanosine; Administration, Oral; Aldehydes; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensins; Animals; Body Weight; Deoxyguanosine; Diabetes Mellitus, Type 2; Disease Models, Animal; Insulin; Islets of Langerhans; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; NADPH Oxidase 2; NADPH Oxidases; Oxidative Stress; Phosphoproteins; Rats; Rats, Inbred OLETF; Rats, Long-Evans; Tetrazoles; Time Factors; Valine; Valsartan	2005
[Effects of enalapril on plasma Ang II level and the expression of AT1 in blood vessel and kidney of type 2 diabetic rats]. Yao xue xue bao = Acta pharmaceutica Sinica, 2005, Volume: 40, Issue:3 Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Vessels; Diabetes Mellitus, Type 2; Dietary Fats; Enalapril; Endothelial Cells; Kidney; Male; Myocytes, Smooth Muscle; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1	2005
Neuronal nitric oxide synthase and cyclooxygenase-2 in diabetic nephropathy of type 2 diabetic OLETF rats. Experimental animals, 2006, Volume: 55, Issue:1 Topics: Angiotensin II; Animals; Cyclooxygenase 2; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Fluorescent Antibody Technique, Indirect; Kidney; Male; Nitric Oxide Synthase Type I; Nitric Oxide Synthase Type II; Rats; Rats, Long-Evans; Renin	2006
The increased angiotensin II (type 1) receptor density in myocardium of type 2 diabetic patients is prevented by blockade of the renin-angiotensin system. Diabetologia, 2006, Volume: 49, Issue:12 Topics: Aged; Angiotensin II; Biopsy; Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Heart Atria; Humans; Male; Middle Aged; Muscle Contraction; Muscle Relaxation; Muscle, Skeletal; Myocardium; Receptor, Angiotensin, Type 1; Reference Values; Renin-Angiotensin System; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger	2006
Adiponectin versus angiotensin II: Key pathological role of their misbalance. Kidney international, 2006, Volume: 70, Issue:10 Topics: Adiponectin; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Humans; Metabolic Syndrome; Obesity; Reactive Oxygen Species; Signal Transduction	2006
Angiotensin II, corticosteroids, type II diabetes and the metabolic syndrome. Medical hypotheses, 2007, Volume: 68, Issue:6 Topics: Adipocytes; Adrenal Cortex Hormones; Angiotensin II; Animals; Diabetes Mellitus, Type 2; Feedback, Physiological; Humans; Insulin Resistance; Metabolic Syndrome; Models, Biological; Renin-Angiotensin System	2007
The metabolic syndrome and the risk of thrombosis. Haematologica, 2007, Volume: 92, Issue:3 Topics: Adiponectin; Adipose Tissue; Angiotensin II; Anthropometry; C-Reactive Protein; Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Cytokines; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Male; Metabolic Syndrome; Obesity; Plasminogen; Prevalence; Prospective Studies; Risk Factors; Stroke; Thrombophilia; Thrombosis; Tissue Plasminogen Activator	2007
Apelin modulates aortic vascular tone via endothelial nitric oxide synthase phosphorylation pathway in diabetic mice. Cardiovascular research, 2007, Jun-01, Volume: 74, Issue:3 Topics: Acetylcholine; Adipokines; Angiotensin II; Animals; Aorta; Apelin; Apelin Receptors; Blotting, Western; Carrier Proteins; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Mice; Mice, Inbred Strains; Models, Animal; Muscle, Smooth, Vascular; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase Type III; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Vasodilation; Vasodilator Agents	2007
An angiotensin II receptor blocker increases sexual behavior in type 2 diabetic mice. Physiology & behavior, 2007, Jun-08, Volume: 91, Issue:2-3 Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Diabetes Mellitus, Type 2; Disease Models, Animal; Exploratory Behavior; Female; Imidazoles; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Inbred Strains; Motor Activity; Reaction Time; Receptor, Angiotensin, Type 1; Sexual Behavior, Animal; Sexual Dysfunction, Physiological; Species Specificity; Tetrazoles; Time Factors	2007
The association between angiotensin II-induced free radical generation and membrane fluidity in neutrophils of patients with metabolic syndrome. The Journal of membrane biology, 2006, Volume: 214, Issue:2 Topics: Adult; Angiotensin I; Angiotensin II; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Female; Fluvastatin; Homeostasis; Humans; Hypercholesterolemia; Indoles; Leukotriene C4; Male; Membrane Fluidity; Metabolic Syndrome; Middle Aged; Neutrophils; Pertussis Toxin; Protein Prenylation; Quinacrine; Signal Transduction; Superoxides; Vasoconstrictor Agents; Vasodilator Agents; Verapamil	2006
PKCdelta regulates the stimulation of vascular endothelial factor mRNA translation by angiotensin II through hnRNP K. Cellular signalling, 2008, Volume: 20, Issue:5 Topics: 3' Untranslated Regions; Angiotensin II; Animals; Cell Line; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Heterogeneous-Nuclear Ribonucleoprotein K; Kidney; Mice; Mice, Inbred C57BL; Mice, Knockout; Phosphorylation; Protein Biosynthesis; Protein Kinase C-delta; RNA, Messenger; Serine; Signal Transduction; Vascular Endothelial Growth Factor A	2008
[The angiotensin II inhibition escape phenomenon in patients with type 2 diabetes and diabetic nephropathy]. Terapevticheskii arkhiv, 2008, Volume: 80, Issue:1 Topics: Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Radioimmunoassay; Renin; Renin-Angiotensin System; Time Factors	2008
Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats. American journal of physiology. Regulatory, integrative and comparative physiology, 2008, Volume: 295, Issue:1 Topics: Aging; Angiotensin II; Animals; Antihypertensive Agents; Diabetes Mellitus, Type 2; Endothelium, Vascular; Imidazoles; Losartan; Nitric Oxide Synthase Type II; omega-N-Methylarginine; Pyridines; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 2; rho-Associated Kinases; Signal Transduction; Up-Regulation; Vasoconstriction; Vasoconstrictor Agents; Vasodilation	2008
Association between left ventricular hypertrophy and erythrocyte sodium-lithium exchange in normotensive subjects with and without NIDDM. Diabetologia, 1995, Volume: 38, Issue:4 Topics: Adult; Aged; Albuminuria; Angiotensin II; Antiporters; Blood Pressure; Body Mass Index; Chi-Square Distribution; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Echocardiography, Doppler, Pulsed; Epinephrine; Erythrocytes; Female; Glycated Hemoglobin; Heart Rate; Humans; Hypertrophy, Left Ventricular; Insulin; Lithium; Male; Middle Aged; Norepinephrine; Regression Analysis; Sodium	1995
The renin-angiotensin system in the type II diabetic obese Zucker rat. Journal of the American Society of Nephrology : JASN, 1993, Volume: 4, Issue:6 Topics: Angiotensin I; Angiotensin II; Animals; Aorta; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; In Vitro Techniques; Male; Norepinephrine; Obesity; Rats; Rats, Zucker; Renin; Renin-Angiotensin System; Vasoconstriction	1993
Acute sodium loading in patients with uncomplicated diabetes mellitus: renal and hormonal effects. Clinical science (London, England : 1979), 1994, Volume: 86, Issue:4 Topics: Adolescent; Adult; Aldosterone; Angiotensin II; Atrial Natriuretic Factor; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Humans; Hypertension; Kidney; Male; Middle Aged; Norepinephrine; Peptides; Renin; Renin-Angiotensin System; Sodium	1994
Angiotensin-converting enzyme activity in retinas of streptozotocin-induced and Zucker diabetic rats. The effect of angiotensin II on Na+,K(+)-ATPase activity. Investigative ophthalmology & visual science, 1996, Volume: 37, Issue:11 Topics: Angiotensin II; Animals; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Imidazoles; Isoenzymes; Lipoxygenase Inhibitors; Losartan; Male; Masoprocol; Peptidyl-Dipeptidase A; Radioimmunoassay; Rats; Rats, Sprague-Dawley; Rats, Zucker; Retina; Sodium-Potassium-Exchanging ATPase; Tetrazoles; Vasoconstrictor Agents	1996
Enhanced effects of insulin and angiotensin II on intracellular pH and free cytosolic calcium in fibroblasts from microalbuminuric patients with non-insulin-dependent diabetes mellitus. Clinical science (London, England : 1979), 1996, Volume: 91, Issue:6 Topics: Aged; Albuminuria; Angiotensin II; Calcium; Cell Culture Techniques; Cytosol; Diabetes Mellitus, Type 2; Female; Fibroblasts; Humans; Hydrogen-Ion Concentration; Insulin; Male; Middle Aged; Skin	1996
Intracellular free calcium abnormalities in fibroblasts from non-insulin-dependent diabetic patients with and without arterial hypertension. Hypertension (Dallas, Tex. : 1979), 1997, Volume: 29, Issue:4 Topics: Aged; Analysis of Variance; Angiotensin II; Biopsy; Bradykinin; Calcium; Cells, Cultured; Diabetes Mellitus, Type 2; Female; Fibroblasts; Humans; Hypertension; Male; Middle Aged; Regression Analysis; Skin	1997
Urinary albumin excretion rate during angiotensin II infusion in microalbuminuric patients with insulin and non-insulin-dependent diabetes mellitus. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 1997, Volume: 12, Issue:2 Topics: Adult; Aged; Albuminuria; Angiotensin II; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged	1997
Augmented Ca2+ influx is involved in the mechanism of enhanced proliferation of cultured vascular smooth muscle cells from spontaneously diabetic Goto-Kakizaki rats. Atherosclerosis, 1997, Volume: 131, Issue:2 Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Angiotensin II; Animals; Aorta, Thoracic; Blood Glucose; Calcium; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Cell Count; Cell Division; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Insulin; Male; Muscle, Smooth, Vascular; Nicardipine; Rats; Rats, Wistar; Vasoconstrictor Agents; Verapamil	1997
Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition. Kidney international, 1997, Volume: 52, Issue:3 Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Enalapril; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Renal Circulation; Renin; Renin-Angiotensin System	1997
Angiotensin blockade improves cardiac and renal complications of type II diabetic rats. Hypertension (Dallas, Tex. : 1979), 1997, Volume: 30, Issue:5 Topics: Albuminuria; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Cilazapril; Coronary Vessels; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Glucose Tolerance Test; Imidazoles; Insulin; Male; Proteinuria; Pyridines; Rats; Rats, Inbred Strains	1997
Elevated sympathetic activity contributes to hypertension and salt sensitivity in diabetic obese Zucker rats. Hypertension (Dallas, Tex. : 1979), 2000, Volume: 35, Issue:1 Pt 2 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Carotid Arteries; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Ganglionic Blockers; Heart Rate; Hexamethonium; Hypertension; Losartan; Male; Obesity; Rats; Rats, Zucker; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin-Angiotensin System; Sodium Chloride, Dietary; Sympathetic Nervous System; Vasoconstriction	2000
Effect of ramipril on cardiovascular events in high-risk patients. The New England journal of medicine, 2000, Jul-06, Volume: 343, Issue:1 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans	2000
Myocardial cell death in human diabetes. Circulation research, 2000, Dec-08, Volume: 87, Issue:12 Topics: Angiotensin II; Apoptosis; Cardiomegaly; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Renin-Angiotensin System; Tyrosine	2000
Plasma levels of tumor necrosis factor-alpha, angiotensin II, growth hormone, and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes care, 2001, Volume: 24, Issue:2 Topics: Adult; Angiotensin II; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; Female; Glucose Clamp Technique; Glucose Intolerance; Glucose Tolerance Test; Human Growth Hormone; Humans; Insulin Resistance; Insulin-Like Growth Factor I; Leptin; Male; Middle Aged; Obesity; Risk Factors; Tumor Necrosis Factor-alpha	2001
Involvement of angiotensin II in progression of renal injury in rats with genetic non-insulin-dependent diabetes mellitus (Wistar fatty rats). Japanese journal of pharmacology, 2001, Volume: 85, Issue:4 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Creatinine; Diabetes Mellitus, Type 2; Disease Progression; Enalapril; Glomerular Mesangium; Male; Proteins; Proteinuria; Rats; Rats, Wistar; Rats, Zucker; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Triglycerides	2001
Plasma angiotensin II, renin activity and serum angiotensin-converting enzyme activity in non-insulin dependent diabetes mellitus patients with diabetic nephropathy. Endocrine journal, 2001, Volume: 48, Issue:1 Topics: Adult; Albuminuria; Angiotensin II; Blood Pressure; Creatinine; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Male; Middle Aged; Peptidyl-Dipeptidase A; Renin	2001
[Inhibition of the renin-angiotensin system in type 2 diabetes. New significant results concerning type 2 diabetes and renal disease]. Ugeskrift for laeger, 2001, Oct-01, Volume: 163, Issue:40 Topics: Angiotensin II; Antihypertensive Agents; Controlled Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Renin-Angiotensin System	2001
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes. The Medical journal of Australia, 2001, Oct-15, Volume: 175, Issue:8 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Biphenyl Compounds; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Hypertension, Renal; Irbesartan; Kidney; Losartan; Male; Primary Prevention; Prognosis; Tetrazoles; Treatment Outcome	2001
Inhibition of the formation or action of angiotensin II reverses attenuated K+ currents in type 1 and type 2 diabetes. The Journal of physiology, 2001, Nov-15, Volume: 537, Issue:Pt 1 Topics: Action Potentials; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Carrier Proteins; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Electric Conductivity; Isoquinolines; Mutation; Potassium Channels; Quinapril; Rats; Rats, Sprague-Dawley; Reaction Time; Receptor, Angiotensin, Type 2; Receptors, Cell Surface; Receptors, Leptin; Saralasin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan	2001
Response of mesangial cells to low-density lipoprotein and angiotensin II in diabetic (OLETF) rats. Kidney international, 2002, Volume: 61, Issue:1 Topics: Angiotensin II; Animals; Cell Count; Cell Division; Cells, Cultured; Cholesterol, LDL; Collagen Type I; Diabetes Mellitus, Type 2; Diabetic Nephropathies; DNA; Extracellular Matrix; Gene Expression; Glomerular Mesangium; Iodine Radioisotopes; Lipoproteins, LDL; Male; Matrix Metalloproteinase 2; Proliferating Cell Nuclear Antigen; Proto-Oncogene Proteins c-fos; Proto-Oncogene Proteins c-myc; Rats; Rats, Inbred OLETF; Receptors, LDL; RNA, Messenger; Transforming Growth Factor beta; Vasoconstrictor Agents	2002
[Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions]. Lakartidningen, 2001, Nov-07, Volume: 98, Issue:45 Topics: Angiotensin II; Antihypertensive Agents; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Follow-Up Studies; Humans; Losartan; Randomized Controlled Trials as Topic	2001
[Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?]. Lakartidningen, 2002, Jan-10, Volume: 99, Issue:1-2 Topics: Angiotensin II; Antihypertensive Agents; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Irbesartan; Randomized Controlled Trials as Topic; Renin-Angiotensin System; Tetrazoles	2002
Thirst and plasma levels of vasopressin, angiotensin II and atrial natriuretic peptide in patients with non-insulin-dependent diabetes mellitus. Diabetes research and clinical practice, 1991, Volume: 11, Issue:3 Topics: Adult; Angiotensin II; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; Diabetes Mellitus, Type 2; Female; Heart Rate; Humans; Male; Middle Aged; Reference Values; Renin; Thirst	1991
Does mild autonomic neuropathy affect atrial natriuretic factor regulation in diabetic hypertensive patients? American journal of hypertension, 1991, Volume: 4, Issue:10 Pt 1 Topics: Adult; Angiotensin II; Atrial Natriuretic Factor; Autonomic Nervous System Diseases; Diabetes Mellitus, Type 2; Diabetic Neuropathies; Humans; Hypertension; Male; Middle Aged; Posture; Renin	1991
Lack of enhanced responsiveness of plasma 18-hydroxycorticosterone and aldosterone to adrenocorticotropin as well as to angiotensin-II during moderate sodium depletion in type II diabetic subjects with normoreninemia. The Journal of clinical endocrinology and metabolism, 1991, Volume: 72, Issue:6 Topics: 18-Hydroxycorticosterone; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Endocrine Glands; Female; Humans; Male; Middle Aged; Reference Values; Renin; Sodium	1991
Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus. The American journal of medicine, 1990, Volume: 88, Issue:3 Topics: Adult; Aged; Aldosterone; Angiotensin II; Blood Pressure; Diabetes Mellitus, Type 2; Diet, Sodium-Restricted; Humans; Hypertension; Middle Aged; Natriuresis; Sodium, Dietary	1990
Plasma 18-hydroxycorticosterone and aldosterone responses to angiotensin II and corticotropin in diabetic patients with hyporeninemic and normoreninemic hypoaldosteronism. Acta endocrinologica, 1989, Volume: 121, Issue:1 Topics: 18-Hydroxycorticosterone; Adrenocorticotropic Hormone; Aldosterone; Angiotensin II; Corticosterone; Diabetes Mellitus, Type 2; Female; Furosemide; Humans; Hypoaldosteronism; Male; Middle Aged; Posture	1989
Renin regulation in type II diabetes mellitus: influence of dietary sodium. Hypertension (Dallas, Tex. : 1979), 1989, Volume: 13, Issue:3 Topics: Aged; Angiotensin II; Chronic Disease; Creatinine; Diabetes Mellitus, Type 2; Humans; Hypertension; Middle Aged; Potassium; Renin; Renin-Angiotensin System; Sodium; Sodium, Dietary; Time Factors	1989
[Studies on hypoaldosteronism associated with diabetes mellitus: response of plasma steroids to angiotensin II or ACTH administration]. Nihon Naibunpi Gakkai zasshi, 1986, Jul-20, Volume: 62, Issue:7 Topics: 18-Hydroxycorticosterone; Adrenocorticotropic Hormone; Adult; Aged; Aldosterone; Angiotensin II; Corticosterone; Desoxycorticosterone; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathies; Female; Humans; Hydrocortisone; Male; Middle Aged; Renin-Angiotensin System	1986